<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Acute chest syndrome (ACS) in sickle cell disease (adults and children)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Acute chest syndrome (ACS) in sickle cell disease (adults and children)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Acute chest syndrome (ACS) in sickle cell disease (adults and children)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joshua J Field, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shaina Willen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elliott P Vichinsky, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael R DeBaun, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 03, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H955280">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute chest syndrome (ACS) is defined as a new radiodensity on chest imaging accompanied by fever and/or respiratory symptoms. It is an acute complication of sickle cell disease (SCD) that is potentially fatal and requires immediate intervention regardless of the patient's age.
        </p>
        <p>
         This topic discusses ACS in adults and children with SCD, including causes, evaluation, management, and prevention.
        </p>
        <p>
         Other pulmonary complications of SCD and general management recommendations are presented separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary complications – (See
         <a class="medical medical_review" href="/z/d/html/7121.html" rel="external">
          "Overview of the pulmonary complications of sickle cell disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary hypertension – (See
         <a class="medical medical_review" href="/z/d/html/94999.html" rel="external">
          "Pulmonary hypertension associated with sickle cell disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management, specialist – (See
         <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">
          "Overview of the management and prognosis of sickle cell disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management, general pediatrician – (See
         <a class="medical medical_review" href="/z/d/html/14519.html" rel="external">
          "Sickle cell disease in infancy and childhood: Routine health care maintenance and anticipatory guidance"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2309813689">
         <span class="h1">
          DEFINITIONS AND PEDIATRIC-ADULT DIFFERENCES
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – The definition of ACS is the same in children and adults: a new radiodensity on chest radiograph together with fever and/or respiratory symptoms. (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         ACS is clinically indistinguishable from pneumonia in individuals with SCD, and with rare exceptions, the distinction largely does not affect management. (See
         <a class="local">
          'Management'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The broad definition of ACS captures a nonspecific clinical endpoint that includes different underlying pathogenic processes. It does not differentiate between a presentation with fever, increased respiratory effort, and a new radiodensity due to bronchiolitis requiring a brief inpatient admission (a more common scenario in children) from intrapulmonary vaso-occlusion and respiratory failure due to fat embolism requiring management in the intensive care unit (a more common scenario in adults).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Children versus adults
         </strong>
         – In addition to differences in triggering events (see
         <a class="local">
          'Common triggers'
         </a>
         below), adults generally have greater disease severity and higher mortality rates, largely due to a higher incidence of bone marrow and fat emboli [
         <a href="#rid1">
          1,2
         </a>
         ]. This and other differences are summarized in the table  (
         <a class="graphic graphic_table graphicRef134346" href="/z/d/graphic/134346.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although the management of ACS episodes is largely the same in adults and children, the greater likelihood of severe ACS in adults highlights the importance of certain interventions such as transfusions. (See
         <a class="local">
          'Acute interventions'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3573985818">
         <span class="h1">
          OVERVIEW OF PATHOGENESIS
         </span>
        </p>
        <p class="headingAnchor" id="H3624784590">
         <span class="h2">
          Risk factors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genotype
         </strong>
         – The more severe SCD genotypes (hemoglobin S [Hb S] and Hb S-beta
         <sup>
          0
         </sup>
         -thalassemia) confer a greater risk for ACS than the less severe genotypes (Hb SC disease [Hb SC] and Hb S-beta
         <sup>
          +
         </sup>
         thalassemia), similar to other vaso-occlusive complications. However, genotype cannot be used to confirm or exclude an ACS diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/7115.html" rel="external">
          "Overview of compound sickle cell syndromes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hb F percentage
         </strong>
         – Higher levels of fetal hemoglobin (Hb F) are protective against SCD complications, but individuals with higher Hb F can still develop ACS [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Comorbidities
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acute pain (especially vaso-occlusive) can increase ACS risk by causing splinting and decreased inspiration.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Asthma and reactive airways dysfunction can cause ventilation perfusion mismatch and inflammatory changes [
         <a href="#rid4">
          4-17
         </a>
         ].
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recent surgery (especially abdominal) can cause atelectasis and increased risk for venous thromboembolism [
         <a href="#rid18">
          18-21
         </a>
         ].
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chronic hypoxemia can reduce perfusion, especially during sleep [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Avascular necrosis and bone (or bone marrow) infarction can cause pulmonary fat embolism.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sedation or opioid analgesics can cause hypoventilation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Environmental factors
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         ACS is more common in winter months due to cold temperature and more frequent upper respiratory infections.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Smoking or second-hand smoke exposure is associated with increased risk of ACS and more severe ACS [
         <a href="#rid4">
          4,24,25
         </a>
         ].
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Exposure to aeroallergens in sensitized individuals may contribute [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Prevention requires diligent care during hospitalization or postoperatively to minimize atelectasis and infection. (See
         <a class="local">
          'Prevention'
         </a>
         below.)
        </p>
        <p>
         Attention to risk factor reduction is an important component of care once the acute ACS episode has subsided. (See
         <a class="local">
          'Discharge planning and outpatient monitoring'
         </a>
         below and
         <a class="local">
          'Risk of ACS recurrence'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1413355795">
         <span class="h2">
          Common triggers
         </span>
         <span class="headingEndMark">
          —
         </span>
         A proximate trigger for an ACS episode can be identified in approximately one-half of individuals [
         <a href="#rid2">
          2,26
         </a>
         ]. Triggers are not mutually exclusive and may coexist in the same individual.
        </p>
        <p>
         In a prospective report from the National Acute Chest Syndrome Study Group (NACSSG) that evaluated 671 episodes of ACS in 538 patients, a definite cause was established in 38 percent of episodes after an extensive evaluation that included bronchial or sputum cultures, blood cultures, and serologic testing (
         <em>
          Mycoplasma pneumoniae
         </em>
         , parvovirus B19, Epstein-Barr virus) [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cause not identified – 46 percent overall; 30 percent in individuals with complete data
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infection
         <em>
         </em>
         – 29 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          Chlamydia pneumoniae
         </em>
         – 7 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          M. pneumoniae
         </em>
         – 7 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Viral (respiratory syncytial virus, parvovirus, rhinovirus) – 6 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mixed – 4 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other – 1 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary infarction – 16 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fat embolism – 9 percent
        </p>
        <p>
        </p>
        <p>
         Infection and asthma are more common causes of ACS in children and a less-common cause in adults [
         <a href="#rid2">
          2,26-28
         </a>
         ]. Vaso-occlusive pain is a more common cause in adults, but pain can also trigger ACS in children. Pulmonary embolism (PE) or pulmonary infarction is documented more often in adults than in children [
         <a href="#rid29">
          29,30
         </a>
         ]. ACS etiologies other than vaso-occlusive pain may also be associated with bone marrow necrosis and fat emboli, such as parvovirus B19 infection [
         <a href="#rid31">
          31
         </a>
         ]. Listing of the most likely causes by age group are discussed in the table  (
         <a class="graphic graphic_table graphicRef134346" href="/z/d/graphic/134346.html" rel="external">
          table 1
         </a>
         ) and below. (See
         <a class="local">
          'Children'
         </a>
         below and
         <a class="local">
          'Adults'
         </a>
         below.)
        </p>
        <p>
         Coronavirus disease 2019 (COVID-19) has been reported as a cause of ACS. (See
         <a class="medical medical_review" href="/z/d/html/128389.html" rel="external">
          "COVID-19: Management in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">
          "COVID-19: Management in hospitalized adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">
          "COVID-19: Management of adults with acute illness in the outpatient setting"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3103899416">
         <span class="h3">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         ACS in children is often triggered by infection. Other common causes include asthma, allergies, infarction, fat embolism, and vaso-occlusive pain. Multiple triggers may be present. In many cases, a proximate cause is not identified.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection
         </strong>
         – Infections are more common as a trigger of ACS in children than in adults and in younger children than older children. The relative frequency of causes was illustrated in the prospective NACSSG study discussed above (see
         <a class="local">
          'Common triggers'
         </a>
         above) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Age ≤9 years
         </strong>
         – Of 329 episodes of ACS, 35 percent were due to infections, especially viral (11 percent), mycoplasma (9 percent), chlamydia (9 percent), and bacterial (4 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Age 10 to 19 years
         </strong>
         – Of 188 episodes of ACS, 22 percent were due to infections, including chlamydia (8 percent), mycoplasma (4 percent), viral (3 percent), and bacterial (3 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a different study involving 141 children with SCD who had positive blood cultures,
         <em>
          Streptococcus pneumoniae
         </em>
         was the most common pathogen (42 percent of total); one-fourth of individuals with positive cultures for
         <em>
          S. pneumoniae
         </em>
         had ACS [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asthma
         </strong>
         – Asthma is common in children with SCD; the prevalence seems to be similar to that in children without SCD. Asthma is associated with a statistically significant and clinically relevant increase in ACS and acute vaso-occlusive pain requiring hospitalization. In a pooled analysis of three studies including 1685 participants with a mean follow-up of 6.1 years (10,216 patient-years), the prevalence of asthma was 23.1 percent (390 of 1685 participants) [
         <a href="#rid33">
          33
         </a>
         ]. After adjustment for age, hemoglobin, and white blood cell count, asthma was associated with higher rates of pain (incidence rate ratio [IRR] 1.34, 95% CI 1.16–1.55,
         <em>
          p
         </em>
         &lt;0.001) and ACS (IRR 1.89, 95% CI 1.61–2.22, p &lt;0.001).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Allergen sensitization
         </strong>
         – Data from a multicenter cohort study demonstrated additive effects of having positive skin prick allergy tests to respiratory allergens on future rates of ACS (IRR 1.23, 95% CI 1.11-1.36, p &lt;0.001) [
         <a href="#rid10">
          10
         </a>
         ]. Even a single positive allergy skin test was associated with an increased risk for ACS; more positive skin tests were associated with greater increases in the rates of future ACS events.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaso-occlusive pain
         </strong>
         – In the NACSSG study, almost half of all patients who developed ACS were initially admitted for other reasons, frequently vaso-occlusive pain [
         <a href="#rid2">
          2
         </a>
         ]. In a different prospective observational study involving 176 children admitted for vaso-occlusive event, 35 developed ACS [
         <a href="#rid34">
          34
         </a>
         ]. Multivariate analysis identified independent risk factors for ACS including high pain score (≥9/10); pain localization to abdomen, spine, or &gt;2 limbs; high reticulocyte count (&gt;260,000/microL); and high neutrophil count (&gt;10,000/microL) at admission. There should be a low threshold for obtaining subsequent chest radiographs in these settings.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2771274343">
         <span class="h3">
          Adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         ACS in adults is often triggered by an acute vaso-occlusive pain episode and/or fat embolism. Infection and asthma are less-common causes. More than one trigger may be present.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaso-occlusive pain and fat embolism
         </strong>
         – In a series of 107 ACS events in 77 adults with SCD, 78 percent were associated with vaso-occlusive pain [
         <a href="#rid35">
          35
         </a>
         ]. A common scenario is development of ACS within 2 to 3 days of the admission for pain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Fat embolism may occur as a consequence of vaso-occlusive pain, and other studies have documented fat embolism as a cause for 44 to 77 percent of ACS episodes in adults [
         <a href="#rid1">
          1,36-45
         </a>
         ]. (See
         <a class="local">
          'Pathophysiology'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Despite the challenging diagnosis of fat emboli as the initiating cause of ACS, significant evidence including bronchioalveolar lavage (BAL; showing fat in alveolar macrophages), post-mortem evaluation, imaging of the bone marrow, and bone marrow aspirate/biopsy (showing bone marrow necrosis) support this diagnosis [
         <a href="#rid36">
          36,38-40,42,43,45
         </a>
         ]. However, since testing for fat emboli requires bronchoscopy and is not performed routinely, the true incidence of fat emboli in patients with ACS is not known. Individuals with hemoglobin SC disease (Hb SC) have been reported to have the highest frequency of fat emboli, especially during pregnancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The correlation between bone marrow infarction and fat embolism is strong. In a study of 20 adults with ACS, 92 percent of the cases demonstrating fat-containing alveolar macrophages by BAL showed some evidence of bone marrow infarction on magnetic resonance imaging (MRI) or radioisotopic bone imaging [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="local">
          'Pathophysiology'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There is a distinct syndrome in some patients with fat embolism that has multisystem involvement and is often not diagnosed until organ failure occurs. (See
         <a class="local">
          'Pathophysiology'
         </a>
         below and
         <a class="local">
          'Rapidly progressive ACS and multiorgan failure'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection
         </strong>
         – In the prospective NACSSG study (see
         <a class="local">
          'Common triggers'
         </a>
         above), 26 percent of ACS episodes in adults were due to infection [
         <a href="#rid2">
          2
         </a>
         ]. Numbers were small overall (153 episodes of ACS in 128 adults &gt;20 years old). Common organisms included chlamydia (9 percent), bacteria (7 percent), mycoplasma (5 percent), and viruses (1 percent). Other organisms included respiratory syncytial virus (RSV) and
         <em>
          Mycoplasma hominis
         </em>
         .
         <em>
          C. pneumoniae
         </em>
         was more common in adolescents and young adults (median age 18 years) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asthma
         </strong>
         – Data from the Cooperative Study of Sickle Cell Disease reported wheezing as a presenting finding in a small proportion of adults (13 percent symptomatic and 8 percent detected on examination) [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2049950354">
         <span class="h2">
          Pathophysiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vaso-occlusion within the pulmonary microvasculature is the basis for ACS pathophysiology. A variety of inciting events (infection, asthma, hypoventilation due to pain, infarction due to fat embolism or venous thromboembolism) can trigger deoxygenation of Hb S leading to polymerization and sickling, leading to vaso-occlusion, ischemia, and endothelial injury [
         <a href="#rid18">
          18,46,47
         </a>
         ]. (See
         <a class="local">
          'Common triggers'
         </a>
         above.)
        </p>
        <p>
         Once vaso-occlusion is initiated in the pulmonary vasculature, it is propagated by hypoxia, inflammation, and acidosis, creating a cycle of ongoing vaso-occlusion. (See
         <a class="medical medical_review" href="/z/d/html/7135.html" rel="external">
          "Pathophysiology of sickle cell disease", section on 'Vaso-occlusion'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypoxia
         </strong>
         – Regional alveolar hypoxia from atelectasis, pulmonary edema, bronchospasm, pneumonia and/or vaso-occlusive pain involving the rib, spine, or abdomen will result in local ventilation-perfusion (V/Q) mismatch and hypoxemia. Focal hypoxia can further increase local sickling. Sedation from opioids can contribute to hypoventilation. In 102 children with SCD who underwent pulmonary function testing, patients with obstructive lung disease had twice the rate of hospitalizations for pain or ACS compared with those with restrictive disease (2.5 versus 1.2 hospitalizations) [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inflammation
         </strong>
         – Infection may trigger release of cytokines and inflammatory mediators. Inflammation associated with fat emboli is likely due to proinflammatory free fatty acids [
         <a href="#rid1">
          1,49
         </a>
         ]. Other contributing factors include endothelial dysfunction, increased expression of vascular adhesion molecules, increased platelet and coagulation factor activation, and disordered nitric oxide metabolism leading to thromboembolism and/or hemolysis [
         <a href="#rid50">
          50,51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vasoconstriction
         </strong>
         – Elevated plasma arginase activity, decreased nitric oxide (NO), and NO synthase gene polymorphisms in patients with SCD may provide a possible biological link between SCD, asthma, and ACS [
         <a href="#rid52">
          52-56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7121.html" rel="external">
          "Overview of the pulmonary complications of sickle cell disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94999.html" rel="external">
          "Pulmonary hypertension associated with sickle cell disease", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Embolism/infarction
         </strong>
         – PE or pulmonary infarction can also cause regional hypoxemia. Pulmonary infarction (and/or in-situ thrombosis) can also occur as a manifestation of local intrapulmonary sickling or vaso-occlusive disease alone (without PE). In one study that used multidetector computed tomography in 144 episodes of ACS in 125 individuals, 17 percent showed evidence of pulmonary thrombosis [
         <a href="#rid30">
          30
         </a>
         ]. Pulmonary thrombi have also been reported in autopsy studies of adults with ACS [
         <a href="#rid57">
          57-61
         </a>
         ]. Findings of sickled RBCs within the thrombi suggest
         <em>
          in situ
         </em>
         thrombosis related to vaso-occlusion rather than emboli originating from deep veins [
         <a href="#rid62">
          62,63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7121.html" rel="external">
          "Overview of the pulmonary complications of sickle cell disease", section on 'Venous thromboembolism and pulmonary thrombosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Fat embolism appears to be a contributing factor in a large number of cases. A study that performed BAL in 20 adults with SCD identified fat-laden macrophages in 12 (60 percent), consistent with fat embolism [
         <a href="#rid36">
          36
         </a>
         ]. A BAL study in 27 children with SCD demonstrated evidence of fat in macrophages in 12 (44 percent); among 43 controls, none had evidence of fat in pulmonary macrophages [
         <a href="#rid43">
          43
         </a>
         ]. Among the 12 children with pulmonary fat embolism, 11 (92 percent) presented with vaso-occlusive pain, whereas only 6 of 15 (40 percent) without pulmonary fat embolism had pain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multiorgan failure
         </strong>
         – There is a distinct syndrome in some patients with fat embolism, with multifocal involvement; fat embolism often is not diagnosed until organ failure occurs. Focal neurologic findings or altered level of consciousness may be caused by small cerebral fat emboli [
         <a href="#rid64">
          64
         </a>
         ]. The pain is often described as the worst pain ever felt, or atypical pain compared with usual vaso-occlusive pain. This is due to massive bone marrow necrosis, often accompanied by a leukoerythroblastic picture on the peripheral blood smear with high nucleated RBC counts. Reports have sporadically identified parvovirus B19 infection [
         <a href="#rid65">
          65
         </a>
         ]. Early diagnosis can reduce mortality but is challenging. Immediate exchange transfusion can be lifesaving [
         <a href="#rid65">
          65,66
         </a>
         ]. (See
         <a class="local">
          'Transfusion'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Bone marrow necrosis with bone marrow and fat emboli is also thought to contribute to the etiology of acute multiorgan failure syndrome [
         <a href="#rid42">
          42,67
         </a>
         ]. (See
         <a class="local">
          'Rapidly progressive ACS and multiorgan failure'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Recurrent episodes of ACS may lead to repeated lung infarctions and parenchymal fibrosis. (See
         <a class="local">
          'Long-term complications'
         </a>
         below.)
        </p>
        <p>
         General mechanisms of vaso-occlusion, hypoxia, and infarction are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7135.html" rel="external">
          "Pathophysiology of sickle cell disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H955287">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data from the Cooperative Study of Sickle Cell Disease (CSSCD), the largest natural history study of SCD that includes both adults and children, suggest that approximately 50 percent of individuals with SCD will have an episode of ACS [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The peak incidence in children is between two to four years [
         <a href="#rid3">
          3
         </a>
         ]. Incidence is higher during the winter months.
        </p>
        <p>
         Data from the CSSCD suggest the following incidence rates [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hb SS (children) – 25.3 per 100 patient-years
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hb SS (adults) – 8.78 per 100 patient-years
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hb SC (children and adults) – 1.95 per 100 patient-years
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hb S-beta
         <sup>
          +
         </sup>
         -thalassemia (children and adults) – 3.27 per 100 patient-years
        </p>
        <p>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H955301">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H1775745469">
         <span class="h2">
          Typical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Presentation and severity are quite variable [
         <a href="#rid68">
          68
         </a>
         ]. Some individuals may present with severe disease, and in others, severe disease may evolve in the two to three days following a pain episode, consistent with fat emboli. Respiratory failure requiring mechanical ventilation occurs in approximately 10 percent [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="local">
          'Respiratory support'
         </a>
         below.)
        </p>
        <p>
         When the initial presentation is mild, there may be chest pain with minimal or no hypoxia/hypoxemia (&lt;4 liters/minute of oxygen via nasal cannula required to maintain oxygen saturation ≥95 percent); there may be no infiltrate on chest imaging or a small infiltrate involving one lobe.
        </p>
        <p>
         Two large cohort studies, the National Acute Chest Syndrome Study Group (NACSSG) and the Cooperative Study of Sickle Cell Disease (CSSCD), have best defined the clinical presentation [
         <a href="#rid2">
          2,3,27
         </a>
         ]. Children accounted for the majority of individuals in both cohorts.
        </p>
        <p>
         Both the NACSSG and CSSCD found chest pain to be a common presenting finding; the CSSCD found fever to predominate.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          NACSSG
         </strong>
         – The NACSSG examined a cohort of 538 adults and children with SCD who had 671 episodes of ACS and reported the following [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Children
         </strong>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Chest pain – 41 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Pain in arms and legs – 30 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Rib and sternal pain – 18 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Shortness of breath – 36 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Neurologic findings – 8 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adults
         </strong>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Chest pain – 55 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Pain in arms and legs – 59 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Rib and sternal pain – 30 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Shortness of breath – 58 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Neurologic findings – 22 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CSSCD
         </strong>
         – The CSSCD examined a cohort of 939 patients with SCD who had 1722 episodes of ACS and reported the following [
         <a href="#rid27">
          27
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Children
         </strong>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Fever – 85 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Chest pain – 41 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Shortness of breath – 20 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Multilobe infiltrates – 24 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Pain preceding the ACS episode – 11 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adults
         </strong>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Fever – 64 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Chest pain – 84 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Shortness of breath – 47 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Multilobe infiltrates – 36 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Pain preceding the ACS episode – 50 percent
        </p>
        <p>
        </p>
        <p>
         Clinical course was more severe in adults; adults were more likely to require mechanical ventilation and to die. These differences must be considered when making treatment decisions. (See
         <a class="local">
          'Management'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3231794507">
         <span class="h2">
          Rapidly progressive ACS and multiorgan failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Up to one-fifth of adults with a history of ACS can develop a distinct ACS phenotype characterized by rapid progression of respiratory compromise, with respiratory failure within 24 hours [
         <a href="#rid69">
          69
         </a>
         ]. Multiorgan failure often occurs.
        </p>
        <p>
         Acute multiorgan failure syndrome is characterized by acute dysfunction of at least two of three organs (lung, liver, and/or kidney) during a vaso-occlusive pain episode [
         <a href="#rid67">
          67
         </a>
         ]. Fever, confusion, decreased hemoglobin, and decreased platelet count are often present [
         <a href="#rid67">
          67
         </a>
         ]. Many patients who present with multiorgan failure have ACS that may not be identified initially. Some of these individuals (especially adults) may have massive fat embolism. (See
         <a class="local">
          'Adults'
         </a>
         above.)
        </p>
        <p>
         In a retrospective cohort, rapidly progressive ACS occurred in 16 of 76 adults (21 percent) and 2 of 97 children (2 percent) [
         <a href="#rid69">
          69
         </a>
         ]. Adults with rapidly progressive ACS had much higher complication rates than adults with ACS that was not rapidly progressive:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute kidney injury (69 versus 3 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatic dysfunction (75 versus 15 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Altered mental status (44 versus 12 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiorgan failure (94 versus 10 percent)
        </p>
        <p>
        </p>
        <p>
         The only predictor of developing rapidly progressive ACS was a decline in platelet count at presentation (odds ratio [OR] 4.8, 95% CI 1.2-19.4) [
         <a href="#rid69">
          69
         </a>
         ]. Mortality was 6 percent in the individuals with rapidly progressive ACS, compared with 0 percent in those without.
        </p>
        <p>
         Since episodes of ACS with fat emboli are often characterized by infiltrates, hypoxia, confusion, and thrombocytopenia during a painful vaso-occlusive episode, these ACS events are likely due to the same underlying etiology of multiorgan failure (bone marrow and fat emboli), with the predominant organ affected being the lung. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
         Neurologic events may complicate ACS, particularly when patients have severe pulmonary disease and/or respiratory failure [
         <a href="#rid2">
          2
         </a>
         ]. In two small studies, reversible posterior leukoencephalopathy syndrome, silent cerebral infarcts, and acute necrotizing encephalitis were reported in children with severe ACS who developed neurologic complications [
         <a href="#rid70">
          70,71
         </a>
         ]. These observations suggest that patients recovering from respiratory failure should be assessed with neurocognitive studies and brain MRI for the presence of silent infarcts [
         <a href="#rid72">
          72
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/106228.html" rel="external">
          "Prevention of stroke (initial or recurrent) in sickle cell disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3969534591">
         <span class="h2">
          COVID-19
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data are limited on the effects of coronavirus disease 2019 (COVID-19) in patients with SCD. However, since SARS-CoV-2 is a respiratory virus that causes pneumonia, we anticipate that infection could lead to ACS and a high risk of death. In a cohort study that included &gt;5000 individuals with SCD compared with &gt;12 million controls, the risk of testing positive for SARS-CoV-2 infection was only mildly increased with SCD (5.7 percent, versus 4.4 percent of controls), but the risk of hospitalization was dramatically higher (0.8 versus 0.2 percent; hazard ratio [HR] 4.1, 95% CI 3.0–5.7) [
         <a href="#rid73">
          73
         </a>
         ]. Consideration of COVID-19, with rapid diagnosis and intervention, can result in excellent recovery [
         <a href="#rid74">
          74,75
         </a>
         ].
        </p>
        <p>
         Any patient with COVID-19 who develops respiratory symptoms should have a type and crossmatch and should be monitored closely for respiratory compromise. If there is a drop in hemoglobin, decrease in hemoglobin oxygen saturation, or both, we would consider initial simple transfusion therapy, with preparation for automated exchange. (See
         <a class="local">
          'Transfusion'
         </a>
         below.)
        </p>
        <p>
         If there is evidence of respiratory compromise, early exchange transfusion to decrease the hemoglobin S to &lt;30 percent of total hemoglobin, in addition to the usual supportive measures and COVID-19 therapies may be lifesaving. If the facility does not have the ability to perform automated exchange transfusion, consideration should be given to transfer the patient to a facility that does have the capacity. (See
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Exchange blood transfusion'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13239723">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H3092800688">
         <span class="h2">
          High level of vigilance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Delays in diagnosis can adversely impact outcomes. A high level of vigilance for ACS should be maintained in any individual with SCD who has:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fever
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory symptoms
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest or back pain
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vaso-occlusive pain in any location
        </p>
        <p>
        </p>
        <p>
         Suspicion for ACS should also be maintained in individuals with SCD admitted to the hospital for
         <strong>
          any
         </strong>
         reason, including those with pain or respiratory symptoms in whom the initial chest radiograph is normal. Individuals with SCD are at increased risk for ACS during hospitalization due to a variety of causes including increased sedation with hypoventilation, splinting with atelectasis, increased inflammation, and others. (See
         <a class="local">
          'Overview of pathogenesis'
         </a>
         above.)
        </p>
        <p>
         Implementation of a standardized clinical protocol or pathway for inpatient monitoring and treatment of early ACS has been demonstrated to improve outcomes [
         <a href="#rid76">
          76,77
         </a>
         ]. Important elements of one protocol included [
         <a href="#rid76">
          76
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of a broad definition for ACS, consisting of lower respiratory symptoms including hypoxemia or a new lung infiltrate
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Close monitoring and quantification of respiratory status using a clinical respiratory score
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Staged escalation of treatment based on the respiratory score
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H262265254">
         <span class="h2">
          Examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vaso-occlusive pain often accompanies ACS and can be intense, severe, and incapacitating. The gold standard for assessment of pain is the individual's (or family/caretaker's) report; no combination of clinical and laboratory findings can determine (or confirm) whether an individual with SCD is in pain. Appropriate pain medication should not be withheld while evaluating for ACS. (See
         <a class="medical medical_review" href="/z/d/html/7144.html" rel="external">
          "Acute vaso-occlusive pain management in sickle cell disease", section on 'Management in the ED and hospital'
         </a>
         .)
        </p>
        <p>
         The examination should focus on:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vital signs and oxygen saturation by pulse oximetry
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sites of pain, especially bone pain in the back and chest
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac and respiratory status
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leg edema and possible deep vein thrombosis (DVT)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of an indwelling catheter and signs of catheter site infection
        </p>
        <p>
        </p>
        <p>
         Pulse oximetry is performed but has two important limitations. First, it tends to
         <strong>
          overestimate
         </strong>
         the presence and frequency of hypoxemia, and may not be accurate as the sole monitor for the respiratory course of patients with severe or progressive ACS [
         <a href="#rid78">
          78,79
         </a>
         ]. Second, it can easily
         <strong>
          underestimate
         </strong>
         the extent of areas of alveolar hypoxia, which lead to sickling, possible infarction, and hypoxic vasoconstriction. (See
         <a class="medical medical_review" href="/z/d/html/1612.html" rel="external">
          "Pulse oximetry"
         </a>
         .)
        </p>
        <p>
         Lipemia retinalis and petechiae are consistent with fat emboli but not commonly seen; their absence does not exclude fat embolism [
         <a href="#rid18">
          18,80
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2302347762">
         <span class="h2">
          Laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following are obtained:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CBC
         </strong>
         – Complete blood count (CBC) with white blood cell (WBC) differential, platelet count, and reticulocyte count, on presentation and repeated daily until clinical improvement. A leukoerythroblastic picture may indicate infection or bone marrow necrosis with massive fat embolism, which can be fatal. (See
         <a class="local">
          'Adults'
         </a>
         above and
         <a class="local">
          'Pathophysiology'
         </a>
         above and
         <a class="local">
          'Rapidly progressive ACS and multiorgan failure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blood bank
         </strong>
         – Type and crossmatch for red blood cell (RBC) transfusions if needed. If at all possible, requested blood should be negative for Hb S, matched for C, E, and Kell, and leukoreduced (leukoreduction is routine at most centers in the United States). The type and crossmatch should remain active throughout the hospitalization based upon the local blood bank requirements. (See
         <a class="local">
          'Transfusion'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'RBC antigen matching'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Percent Hb S
         </strong>
         – If exchange transfusions are used, the percent Hb S is monitored before and after each procedure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metabolic panel
         </strong>
         – Used to assess and monitor kidney and liver function. Many individuals with SCD have hyperfiltration (especially when younger) or impaired kidney function (when older). Markers for massive bone marrow necrosis such as serum ferritin and lactate dehydrogenase (LDH) may be helpful in selected cases [
         <a href="#rid64">
          64-66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cultures
         </strong>
         – Cultures (blood, sputum) and other appropriate infectious disease testing if fever is present. (See
         <a class="medical medical_review" href="/z/d/html/5937.html" rel="external">
          "Evaluation and management of fever in children and adults with sickle cell disease", section on 'Diagnostic testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          COVID-19
         </strong>
         – During the coronavirus disease 2019 (COVID-19) pandemic, testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is appropriate for all individuals with SCD who present with fever, chest pain, decreased oxygen saturation, or respiratory symptoms, regardless of whether they have already had COVID-19 or have received a COVID-19 vaccine.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Limited role for ABG
         </strong>
         – We generally do
         <strong>
          not
         </strong>
         obtain arterial blood gasses (ABGs) unless there is significant respiratory distress or signs of impending respiratory collapse and need for intubation. Blood gas may be useful if there is significant respiratory distress, impending respiratory failure, inconsistency between the pulmonary clinical status and recordings from pulse oximetry, or to provide additional data to determine the need for simple or exchange transfusion (eg, PaO
         <sub>
          2
         </sub>
         &lt;60 mm Hg). (See
         <a class="medical medical_review" href="/z/d/html/6327.html" rel="external">
          "Arterial puncture and cannulation in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1648.html" rel="external">
          "Arterial blood gases"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If respiratory failure is present, it is important to distinguish pure hypoxemic respiratory failure from mixed hypercapnic-hypoxemic respiratory failure. (See
         <a class="local">
          'Respiratory support'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Laboratory markers are not available to predict which patients with vaso-occlusive pain are at risk for ACS, although some markers such as secretory phospholipase A2 (sPLA2) and C-reactive protein (CRP) are under investigation. Both sPLA2 and CRP increase hours before the development of ACS [
         <a href="#rid52">
          52,81,82
         </a>
         ]. In one small unblinded randomized trial of patients with SCD-associated pain and an elevated sPLA2, the addition of single transfusion to standard therapy appeared to reduce the risk of developing ACS [
         <a href="#rid83">
          83
         </a>
         ]. Further study is needed to determine the usefulness of these markers.
        </p>
        <p class="headingAnchor" id="H33318346">
         <span class="h2">
          Imaging
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging for new lung density
         </strong>
         – Chest imaging (typically, anteroposterior [AP] and lateral chest radiographs) should be obtained for all individuals with SCD who have fever, chest pain, decreased oxygen saturation, or respiratory symptoms. Often the radiologist cannot distinguish between an infiltrate or atelectasis; we prefer to refer to the new lung finding as new radiodensity rather than an infiltrate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one study of febrile patients with SCD, 61 percent were not clinically suspected by evaluating clinicians prior to the diagnosis by chest radiograph [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Chest radiograph
         </strong>
         – A chest radiograph should be obtained for all patients admitted with severe vaso-occlusive pain, particularly with chest or rib pain. Patients who demonstrate restrictive respiratory efforts and/or hypoxemia at rest should have repeat chest radiographs within 24 to 48 hours after admission, because ACS frequently develops after admission for a pain episode [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ultrasound
         </strong>
         – Bedside chest ultrasound is not standard but may be performed by some experts. It may allow rapid diagnosis and allow patients to avoid radiation from chest radiographs [
         <a href="#rid85">
          85,86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A new radiodensity with one of the other findings listed below is sufficient to diagnose ACS [
         <a href="#rid2">
          2,3,27,87-89
         </a>
         ]. (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging for pulmonary embolism (PE)
         </strong>
         – PE should be considered in individuals with ACS and progressive respiratory difficulty where the cause remains obscure, especially when there is rapid clinical deterioration with worsening hypoxemia and/or cardiac dysfunction [
         <a href="#rid90">
          90
         </a>
         ]. Observational studies suggest that PE is not rare in individuals with ACS (17 percent in one series) [
         <a href="#rid91">
          91
         </a>
         ]. Many patients with PE will not have a demonstrable DVT on leg imaging [
         <a href="#rid30">
          30
         </a>
         ]. If PE is diagnosed, anticoagulation is appropriate. Diagnosis and management are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5916.html" rel="external">
          "Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H784769269">
         <span class="h2">
          Additional testing in selected individuals
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional testing may be indicated on a case-by-case basis depending on clinical suspicion and prior history:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Computed tomography pulmonary angiography (CT-PA) of the chest to evaluate for PE. (See
         <a class="medical medical_review" href="/z/d/html/5918.html" rel="external">
          "Venous thrombosis and thromboembolism (VTE) in children: Risk factors, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electrocardiogram (ECG) and serial serum troponin levels to evaluate for myocardial damage. If myocardial damage is identified, it may indicate acute multiorgan failure syndrome, and transfusion may be required if not already administered [
         <a href="#rid42">
          42,67
         </a>
         ]. (See
         <a class="local">
          'Rapidly progressive ACS and multiorgan failure'
         </a>
         above and
         <a class="local">
          'Transfusion'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bronchoscopy with bronchoalveolar lavage (BAL) is invasive and not standard care. It is typically reserved for refractory disease or atypical presentations in which BAL would provide important information that would change management. (See
         <a class="medical medical_review" href="/z/d/html/4303.html" rel="external">
          "Basic principles and technique of bronchoalveolar lavage"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15928837">
         <span class="h2">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         ACS is defined by a new pulmonary density on chest imaging involving at least one complete lung segment
         <strong>
          and
         </strong>
         at least one of the following [
         <a href="#rid68">
          68
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Temperature ≥38.5°C
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         &gt;3 percent decrease in SpO
         <sub>
          2
         </sub>
         (oxygen saturation) from a documented steady-state value on room air
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tachypnea (per age-adjusted normal)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intercostal retractions, nasal flaring, or use of accessory muscles of respiration
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest pain
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cough
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wheezing
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rales
        </p>
        <p>
        </p>
        <p>
         Pneumonia can formally be considered as meeting the criteria for ACS (the two cannot be reliably distinguished).
        </p>
        <p class="headingAnchor" id="H369889376">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis includes other pulmonary complications of SCD and other conditions that cause chest pain, respiratory distress, or densities on chest radiography. Pneumonia cannot be reliably distinguished from ACS on clinical grounds, nor does it need to be, as management is similar.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SCD complications
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Vaso-occlusive pain
         </strong>
         – Vaso-occlusive pain often precedes ACS and can accompany or exacerbate ACS, especially in adults; the presence of vaso-occlusive pain does not eliminate the possibility of ACS. Isolated vaso-occlusive pain does not cause an infiltrate on chest imaging. However, chest wall pain in the ribs and sternum can occur during a pain episode and can cause splinting, which could lead to ACS.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Severe anemia or splenic/hepatic sequestration
         </strong>
         – Severe anemia or splenic/hepatic sequestration can accompany or complicate ACS; the presence of these findings does not eliminate the possibility of ACS. Like ACS, severe anemia or splenic or hepatic sequestration can cause dyspnea and in some cases chest pain. Unlike ACS, these complications do not cause an infiltrate on chest imaging.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Multiorgan failure syndrome
         </strong>
         – Multiorgan failure can accompany or complicate ACS; the presence of multiorgan failure does not eliminate the possibility of ACS. Exchange transfusions and respiratory support treat multiorgan failure and severe ACS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other causes of chest pain or respiratory distress
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Rib fracture
         </strong>
         – Like ACS, rib fracture can cause acute chest pain. Unlike ACS, rib fracture is usually obvious on chest imaging.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Asthma
         </strong>
         – Asthma can accompany or exacerbate ACS, especially in children; its presence does not eliminate the possibility of ACS. Unlike ACS, asthma does not cause an infiltrate on chest imaging.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          PE
         </strong>
         – Pulmonary embolism (PE) can accompany or exacerbate ACS, especially in adults; its presence does not eliminate the possibility of ACS. A history of recent surgery or immobility, or evidence of deep vein thrombosis (DVT) on leg ultrasound, supports the diagnosis of PE but does not eliminate ACS. Identifying a PE is important because anticoagulation is required, and anticoagulation is not a routine component of ACS management.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pulmonary hypertension
         </strong>
         – Pulmonary hypertension is a chronic complication of SCD that can cause dyspnea and other findings, typically in adults. (See
         <a class="medical medical_review" href="/z/d/html/94999.html" rel="external">
          "Pulmonary hypertension associated with sickle cell disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Heart failure/pulmonary edema
         </strong>
         – Like ACS, heart failure or pulmonary edema can cause dyspnea and infiltrates on chest imaging. Unlike ACS, heart failure and pulmonary edema do not typically cause chest pain, and the infiltrates respond to diuresis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Myocardial ischemia/infarction
         </strong>
         – Cardiac ischemia can accompany, exacerbate, or complicate ACS, especially in older adolescents and adults; the presence of cardiac ischemia does not eliminate the possibility of ACS, and the presence of ACS does not eliminate the possibility of cardiac ischemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Presenting findings in acute myocardial infarction may differ in individuals with SCD. In a series of over 2 million admissions for acute myocardial infarction, in which SCD was reported in 501 (0.02 percent), the individuals with SCD were
         <strong>
          less likely
         </strong>
         to have risk factors for coronary artery disease and
         <strong>
          more likely
         </strong>
         to have comorbidities including pneumonia, respiratory failure or need for mechanical ventilation, and acute kidney injury or need for dialysis [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H955343">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vigilance for ACS is important so that early and escalated interventions can be started without delay. (See
         <a class="local">
          'High level of vigilance'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1990137710">
         <span class="h2">
          Acute interventions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prompt intervention for ACS is essential to prevent clinical deterioration and death [
         <a href="#rid68">
          68
         </a>
         ]. Moderate to severe ACS is typically managed in the intensive care unit (ICU).
        </p>
        <p class="headingAnchor" id="H483671930">
         <span class="h3">
          Pain control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pain control should be immediate and analgesic dosing adequate to control pain, which can be severe. Assessment of pain control should be based on the patient's report (or family members/caregivers if needed). (See
         <a class="local">
          'Examination'
         </a>
         above.)
        </p>
        <p>
         In addition to reducing pain, adequate analgesia can help reduce hypoventilation and atelectasis.
        </p>
        <p>
         Details of pain management are presented in detail separately and summarized briefly here (see
         <a class="medical medical_review" href="/z/d/html/7144.html" rel="external">
          "Acute vaso-occlusive pain management in sickle cell disease"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pain control with parenteral opioids, typically delivered by patient-controlled analgesia (PCA), is generally required to treat ACS episodes in adults. Opioids are also appropriate for children with severe pain. Careful attention to dosing is required to avoid oversedation, hypoventilation, and atelectasis. PCA may minimize oversedation and hypoventilation while providing adequate pain control. (See
         <a class="medical medical_review" href="/z/d/html/7144.html" rel="external">
          "Acute vaso-occlusive pain management in sickle cell disease", section on 'Continuous opioids/patient-controlled analgesia (PCA)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">
          Ketorolac
         </a>
         is sometimes used briefly in children as a nonsedating analgesic in the acute setting but is often avoided in adults due to potential toxicities, including acute kidney injury. An example pediatric dose is 0.5 mg/kg intravenously (maximum dose 30 mg), followed by 0.5 mg/kg intravenously (maximum dose 15 mg) every six hours for up to three or five days, with close monitoring of kidney function. Other nonsteroidal antiinflammatory drugs (NSAIDs) should
         <strong>
          not
         </strong>
         be used concurrently. (See
         <a class="medical medical_review" href="/z/d/html/7144.html" rel="external">
          "Acute vaso-occlusive pain management in sickle cell disease", section on 'Therapies we do not use'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Patients should be ambulated as soon as possible once adequate pain control is achieved.
        </p>
        <p class="headingAnchor" id="H2723168171">
         <span class="h3">
          Respiratory support
         </span>
         <span class="headingEndMark">
          —
         </span>
         Respiratory support may include supplemental oxygen, non-invasive ventilation, or intubation and mechanical ventilation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring
         </strong>
         – Careful monitoring of respiratory status in patients with ACS is essential to determine the best approach and react to changes in the patient's clinical status. The monitoring protocol should include scheduled semiquantitative assessments of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Respiratory rate
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Auscultation (air movement, wheezing, rales)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use of accessory muscles of respiration
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mental status
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Color and perfusion
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Oxygen saturation by pulse oximetry (SpO
         <sub>
          2
         </sub>
         ) and associated tissue hypoxemia, which may be more severe than indicated by SpO
         <sub>
          2
         </sub>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These assessments should be performed on a regular schedule (eg, every four hours), and an algorithm should be designed that alerts the treating team to a need for advanced level of care, advanced respiratory support to avoid need for mechanical ventilation, and to guide timing of transfusion therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Vasoconstriction, hypotension, and hypothermia can also affect SpO
         <sub>
          2
         </sub>
         values because the basis for these measurements is light absorbed from fingertip blood flow and the equation is derived from a hemoglobin dissociation curve based on hemoglobin A and not hemoglobin S [
         <a href="#rid93">
          93
         </a>
         ]. Co-oximetry measures different types of hemoglobin and provides the most accurate measure of oxygen saturation in patients with SCD. Most arterial blood gas (ABG) analyzers in the United States use co-oximetry to measure oxygen saturation. We rarely obtain ABGs, unless there are comorbidities and extenuating clinical situations; ABGs may be appropriate in selected cases with clinical deterioration, significant respiratory distress, or signs of impending respiratory collapse. (See
         <a class="local">
          'Laboratory testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oxygen
         </strong>
         – Supplemental oxygen should be provided to individuals with dyspnea and respiratory distress, and to maintain arterial oxygen saturation ≥95 percent or at the level of the patient's baseline SpO
         <sub>
          2
         </sub>
         . The value of ≥95 percent is based on clinical experience; 2014 guidelines on management of SCD recommend a value of &gt;95 percent, based on low quality evidence [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is important to use a higher target for SpO
         <sub>
          2
         </sub>
         than is used for other patient populations, due to the SCD disease physiology and risk of other complications. An SpO
         <sub>
          2
         </sub>
         &lt;96 percent is associated with increased risk of stroke and vaso-occlusive pain. If the patient is known to have a steady state SpO
         <sub>
          2
         </sub>
         &lt;95 percent, a comparison to the baseline value is helpful. Typically an absolute change of more than 3 percentage points is considered clinically significant [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While SpO
         <sub>
          2
         </sub>
         can be used as a guide, it does not always reflect true tissue oxygenation. ABG may be helpful in some cases, although it should not be used indiscriminately.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Calculated oxygen saturation is based on a normal oxyhemoglobin dissociation curve, while patients with SCD have a right-shifted curve due to the presence of hemoglobin S [
         <a href="#rid95">
          95
         </a>
         ]. Local sickling can reduce tissue oxygenation significantly, and SpO
         <sub>
          2
         </sub>
         -derived measurements of hemoglobin oxygen saturation typically underestimate oxygen pressure [
         <a href="#rid93">
          93,96
         </a>
         ]. Consequently, it may be appropriate to provide additional oxygen if there are signs of tissue hypoxia. Hypoxia promotes sickling, and local tissue hypoxia can worsen sickling in tissues with reduced perfusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If adequate oxygenation cannot be achieved with a face mask, noninvasive or invasive ventilation may be required, along with other interventions including exchange transfusion. (See
         <a class="local">
          'Transfusion'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Incentive spirometry
         </strong>
         – Incentive spirometry with 10 maximal inspirations, preferably supervised, should be encouraged at least every two hours while awake to prevent ACS in those admitted to the hospital with acute vaso-occlusive pain [
         <a href="#rid97">
          97-99
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Noninvasive ventilation
         </strong>
         – For patients with rising oxygen requirements or decreasing respiratory effort, noninvasive ventilation may be useful, such as nasal mask continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BPAP) [
         <a href="#rid47">
          47,100,101
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5747.html" rel="external">
          "Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management", section on 'Noninvasive positive pressure ventilation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intubation
         </strong>
         – Intubation is used for standard indications. In the National Acute Chest Syndrome Study Group (NACSSG) study, 13 percent of patients required mechanical ventilation for respiratory failure [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/109649.html" rel="external">
          "Initiating mechanical ventilation in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1640.html" rel="external">
          "Overview of initiating invasive mechanical ventilation in adults in the intensive care unit"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with respiratory failure and acute respiratory distress syndrome (ARDS), conventional or high-frequency oscillatory mechanical ventilation can be used. In intubated patients with persistent hypoxemia, bronchoscopy with suction and removal of bronchial casts has been reported to improve patient ventilation [
         <a href="#rid102">
          102,103
         </a>
         ]. It is important to distinguish pure hypoxemic respiratory failure from a mixed hypercapnic-hypoxemic respiratory failure. (See
         <a class="medical medical_review" href="/z/d/html/6463.html" rel="external">
          "Acute respiratory distress in children: Emergency evaluation and initial stabilization"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1458.html" rel="external">
          "The evaluation, diagnosis, and treatment of the adult patient with acute hypercapnic respiratory failure"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ECMO
         </strong>
         – If mechanical ventilation is insufficient, extra corporeal membrane oxygenation (ECMO) may be used. Efficacy of ECMO in ACS has been described in case reports [
         <a href="#rid104">
          104,105
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6392.html" rel="external">
          "Pediatric advanced life support (PALS)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1625.html" rel="external">
          "Extracorporeal life support in adults in the intensive care unit: Overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3233793933">
         <span class="h3">
          Bronchodilators
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bronchodilators are commonly used in ACS, especially for children, despite the lack of high-quality supporting evidence and absence of randomized trials [
         <a href="#rid18">
          18,106
         </a>
         ]. Bronchodilators are used less frequently in adults, for whom wheezing is a less-common presentation. (See
         <a class="local">
          'Typical presentation'
         </a>
         above.)
        </p>
        <p>
         Potential uses of a bronchodilator during an ACS episode include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wheezing, regardless of asthma history.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of reactive airways disease or asthma, regardless of whether wheezing is currently present.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Progressive respiratory distress during an ACS episode.
        </p>
        <p>
        </p>
        <p>
         In the NACSSG, bronchodilators were administered to 61 percent of participants during an episode of ACS; clinical improvement (defined as &gt;15 percent increase in FEV
         <sub>
          1
         </sub>
         ) was reported in 20 percent [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         A review of bronchodilators in ACS among large pediatric hospitals in North America between 2005 and 2011 identified wide variation in bronchodilator use (0 to 97 percent) [
         <a href="#rid107">
          107
         </a>
         ]. Overall, bronchodilator use was associated with a 13 percent increase in length of stay, however for the subgroup with asthma, bronchodilator use was associated with an 18 percent decrease in length of stay.
        </p>
        <p class="headingAnchor" id="H2612773871">
         <span class="h3">
          Antibiotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with ACS require broad spectrum antibiotics. Infection is one of the most common causes of ACS in children and affects a significant proportion of adults with ACS, and individuals with SCD are immunocompromised due to absent splenic function, placing them at risk of life-threatening sepsis, especially with encapsulated organisms.
        </p>
        <p>
         Antibiotics should be administered immediately due to the risk of life-threatening infection [
         <a href="#rid99">
          99
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5937.html" rel="external">
          "Evaluation and management of fever in children and adults with sickle cell disease", section on 'Risk of life-threatening infection'
         </a>
         .)
        </p>
        <p>
         Antibiotic selection depends on clinical severity and findings that suggest a specific organism:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Empiric antibiotic therapy for community-acquired pneumonia includes coverage for atypical bacteria, typically with a macrolide and a third generation cephalosporin [
         <a href="#rid26">
          26,28
         </a>
         ]. A fourth-generation fluoroquinolone is another option [
         <a href="#rid2">
          2
         </a>
         ]. These antibiotics cover typical organisms seen in ACS, including atypical bacteria (
         <em>
          Chlamydia
         </em>
         and
         <em>
          Mycoplasma
         </em>
         ) along with
         <em>
          S. pneumonia
         </em>
         and
         <em>
          Haemophilus influenzae
         </em>
         . (See
         <a class="local">
          'Common triggers'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6989.html" rel="external">
          "
          <i>
           Mycoplasma pneumoniae
          </i>
          infection in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7013.html" rel="external">
          "Pneumococcal pneumonia in patients requiring hospitalization"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Example regimens for adults include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">
          Cefotaxime
         </a>
         1 to 2 grams intravenously every eight hours plus
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         500 mg orally or intravenously once daily for seven days
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         or-
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          Moxifloxacin
         </a>
         400 mg orally or intravenously for seven days
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Additional antibiotic options, considerations for individuals with fever and penicillin allergy (use of
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         ), and concerns about ceftriaxone-induced hyperhemolysis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5937.html" rel="external">
          "Evaluation and management of fever in children and adults with sickle cell disease", section on 'Antibiotic selection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For a severely ill individual with large or progressive pulmonary infiltrates, addition of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         may be appropriate to cover bacteria that are resistant to cephalosporins, such as methicillin resistant
         <em>
          Staphylococcus aureus
         </em>
         (MRSA).
        </p>
        <p>
        </p>
        <p>
         In the absence of severe or life-threatening pneumonia (
         <em>
          S. aureus
         </em>
         pneumonia), we generally treat for a total of 7 to 10 days. For patients treated with
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         , the duration is five days.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          Acetaminophen
         </a>
         should be prescribed at appropriate doses for fever.
        </p>
        <p class="headingAnchor" id="H1884746214">
         <span class="h3">
          Transfusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transfusion is considered the mainstay of therapy for ACS, despite an absence of high quality randomized trials demonstrating efficacy [
         <a href="#rid108">
          108
         </a>
         ]. Transfusion therapy is used because it improves oxygenation [
         <a href="#rid2">
          2,109,110
         </a>
         ].
        </p>
        <p>
         In the NACSSG study, 72 percent of patients received transfusions (two-thirds of these were simple transfusions), and the partial pressure of oxygen while breathing room air increased from 63 mmHg before transfusion to 71 mmHg after transfusion [
         <a href="#rid2">
          2
         </a>
         ]. Oxygen saturation increased from 91 to 94 percent. Simple and exchange transfusions resulted in similar improvements of oxygenation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Decisions
         </strong>
         – The main decisions are:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         When to use transfusion
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Whether to use simple transfusion or red blood cell (RBC) exchange
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         What hemoglobin and percent Hb S to target
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – Transfusion is generally indicated for any individual hospitalized with ACS. The consequences of not transfusing can be disastrous. The most important risk factor for death is the rapidity of respiratory deterioration, regardless of the number of lobes involved. In our experience, prompt transfusion has decreased the progression from mild to moderate or severe ACS in many cases [
         <a href="#rid77">
          77
         </a>
         ]. Exceptions in which transfusion may be deferred include patients who are stable without severe hypoxia or other indicators of clinical deterioration. If transfusion is deferred, close monitoring is needed so that any changes in clinical status are rapidly appreciated and acted upon.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Simple versus exchange transfusion
         </strong>
         – A reasonable approach to determining the type of transfusion is to evaluate and monitor clinical respiratory effort, hemoglobin oxygen saturation, and hemoglobin level [
         <a href="#rid18">
          18,68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Simple transfusion
         </strong>
         – Simple transfusion can be administered rapidly without the need for blood bank personnel or specialized equipment. The goal of simple transfusion is to increase the hematocrit to 30 percent or the hemoglobin to 10 g/dL, as a means of reducing sickling and improving oxygenation [
         <a href="#rid111">
          111,112
         </a>
         ]. Caution should be used not to increase the hemoglobin above 11 g/dL due to the risk of hyperviscosity. Simple transfusion is appropriate for:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Oxygen saturation &lt;95 percent on room air.
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hemoglobin &lt;5 g/dL.
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hematocrit or hemoglobin 10 to 20 percent below the patient's baseline.
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Decreasing hemoglobin or hematocrit during hospitalization.
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Clinical or radiological progression of disease without impending respiratory failure.
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         As a temporizing measure while awaiting/preparing for exchange transfusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Exchange transfusion
         </strong>
         – Exchange transfusion allows transfusion of a large blood volume (6 to 8 units of RBCs in an adult) that can dramatically lower the percentage of Hb S and decrease vaso-occlusion without risking hyperviscosity. The goal of exchange transfusion should be to decrease the Hb S to &lt;30 percent of the total hemoglobin concentration [
         <a href="#rid111">
          111-113
         </a>
         ]. Exchange transfusion can be safely performed in individuals with ACS; one series described use of exchange transfusion in 53 ACS episodes (44 patients) without any complications [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Exchange transfusion is appropriate for individuals with:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Previous history of severe ACS or cardiopulmonary disease.
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Multilobar disease (&gt;1 lobe affected) on chest imaging.
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Rapidly progressive ACS or multiorgan failure syndrome.
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Progression of ACS despite simple transfusion.
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Severe hypoxemia (SaO
         <sub>
          2
         </sub>
         ≤85 percent or PaO
         <sub>
          2
         </sub>
         ≤55 mm Hg).
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Declining SpO
         <sub>
          2
         </sub>
         readings despite increasing oxygen delivery, particularly if the declining oxygen saturation occurs over a brief period of several hours. In practice, we rarely obtain an ABG unless the patient is in the ICU and has an arterial line placed.
        </p>
        <p>
        </p>
        <p>
         The capability to perform exchange transfusion varies by institution. If the patient is at a facility that does not have the ability to perform automated exchange transfusion, we highly recommend that consideration be given to transfer the patient to a facility that does have the capacity for automated exchange transfusion.
        </p>
        <p>
         Additional comparisons between simple transfusion and exchange transfusion are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Simple versus exchange transfusion'
         </a>
         .)
        </p>
        <p>
         Additional transfusion considerations (phenotypic and extended crossmatching, avoidance of donors with sickle cell trait) are also presented separately. (See
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Transfusion techniques'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H914899236">
         <span class="h3">
          Fluid management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypervolemia in SCD is associated with prolonged hospitalization compared with euvolemia [
         <a href="#rid115">
          115
         </a>
         ].
        </p>
        <p>
         Fluids should be administered to prevent hypovolemia, as would be the case for any hospitalized patient. The typical regimen is 1.5 times maintenance fluids of D5 in one-half normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         for the first 24 to 48 hours. Thereafter, the rate can be decreased as the patient begins to drink fluids. Euvolemia should be maintained using hypotonic oral and intravenous fluids with the rate of fluid administration adjusted to the clinical status and needs of the patient (more fluids needed if fever is present). (See
         <a class="medical medical_review" href="/z/d/html/7144.html" rel="external">
          "Acute vaso-occlusive pain management in sickle cell disease", section on 'Hydration'
         </a>
         .)
        </p>
        <p>
         Fluid balance should be monitored frequently to avoid fluid overload. Overhydration or rapid hydration should be avoided because they may result in pulmonary edema or heart failure.
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          Furosemide
         </a>
         may be helpful if fluid overload is suspected. Weights should be monitored daily along with intake/output for assessment of the fluid status and management of the patient.
        </p>
        <p>
         Calculators are available to help estimate the daily fluid requirement (
         <a class="calc calc_professional" href="/z/d/html/13425.html" rel="external">
          calculator 1
         </a>
         ) or the hourly requirement (
         <a class="calc calc_professional" href="/z/d/html/121761.html" rel="external">
          calculator 2
         </a>
         ) in children. (See
         <a class="medical medical_review" href="/z/d/html/6122.html" rel="external">
          "Maintenance intravenous fluid therapy in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H558987352">
         <span class="h3">
          VTE prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         ACS is an acute medical illness that predisposes patients to venous thromboembolism (VTE). All adults with ACS should receive VTE prophylaxis. (See
         <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">
          "Overview of the management and prognosis of sickle cell disease", section on 'Thromboembolism prophylaxis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">
          "Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"
         </a>
         .)
        </p>
        <p>
         We do not use routine thromboprophylaxis for VTE in hospitalized children &lt;18 years of age with SCD unless there are predisposing risk factors. (See
         <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">
          "Overview of the management and prognosis of sickle cell disease", section on 'Thromboembolism prophylaxis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5916.html" rel="external">
          "Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1522437601">
         <span class="h3">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of glucocorticoids for ACS remains unclear. We generally do not use glucocorticoids in children or adults with SCD, and glucocorticoids are not considered part of standard practice. An exception may be an individual with evidence of reactive airways disease or asthma exacerbation, or those with rapidly progressive ACS. If a glucocorticoid is used, it should be tapered to reduce the risk of rebound vaso-occlusion. (See
         <a class="medical medical_review" href="/z/d/html/7121.html" rel="external">
          "Overview of the pulmonary complications of sickle cell disease", section on 'Asthma'
         </a>
         and
         <a class="local">
          'Rapidly progressive ACS and multiorgan failure'
         </a>
         above.)
        </p>
        <p>
         Clinical trials have reported mixed results regarding efficacy, and several have suggested possible increased risk of rebound vaso-occlusive complications:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A randomized trial that assigned 38 children hospitalized with a total of 43 episodes of mild to moderately severe ACS to receive intravenous
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         or placebo [
         <a href="#rid116">
          116
         </a>
         ]. The dexamethasone group had better outcomes, including a shorter median length of hospital stay (47 versus 80 hours), less clinical deterioration, less use of opioids, and less need for blood transfusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective study involving 5247 hospitalizations for ACS in children from 32 hospitals in the Pediatric Health information System database in the United States, glucocorticoid use was associated with a significantly longer length of hospital stay (25 percent, 95% CI 14-38 percent) and a higher three-day readmission rate (odds ratio [OR] 2.3, 95% CI 1.6-3.4) [
         <a href="#rid117">
          117
         </a>
         ]. Children who received glucocorticoids were more likely to have asthma.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective study involving 129 episodes of ACS in 65 individuals &lt;22 years of age, use of glucocorticoids was associated with increased risk of readmission (OR 20, P &lt;0.005) and longer hospitalization [
         <a href="#rid118">
          118
         </a>
         ]. Readmission also correlated with other risk factors such as use of an inhaler or nebulizer at home. Another retrospective study in individuals treated with glucocorticoids for vaso-occlusive pain also reported an increased risk of rebound pain following treatment with a glucocorticoid [
         <a href="#rid119">
          119
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4244494462">
         <span class="h3">
          Inhaled nitric oxide
         </span>
         <span class="headingEndMark">
          —
         </span>
         Case studies have reported inhaled nitric oxide (iNO), a selective pulmonary vasodilator, improved ventilation/perfusion mismatch, and decreased pulmonary hypertension [
         <a href="#rid120">
          120,121
         </a>
         ]. iNO also increases the oxygen affinity of Hb S, thus potentially decreasing sickling of RBCs [
         <a href="#rid122">
          122
         </a>
         ]. However, a randomized trial from 2015 found no benefit from iNO in ACS, and we do not use this strategy [
         <a href="#rid123">
          123
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3897843020">
         <span class="h2">
          Discharge planning and outpatient monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thoughtful discharge planning is essential to minimize the risk of ACS recurrence, which is high, as well as other chronic complications that may be less common but carry high risks of morbidity and even mortality. (See
         <a class="local">
          'Risk of ACS recurrence'
         </a>
         below and
         <a class="local">
          'Long-term complications'
         </a>
         below.)
        </p>
        <p>
         A comprehensive, multidisciplinary approach between a hematologist and pulmonologist is ideal, especially if the individual has other lung disease besides ACS [
         <a href="#rid33">
          33
         </a>
         ]. A baseline assessment may include evaluation for the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep apnea
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asthma, especially in children
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other risk factors for pulmonary disease (smoking or second-hand smoke exposure)
        </p>
        <p>
        </p>
        <p>
         Clinicians should be alert for evidence of airway hyperreactivity in patients with SCD and should pursue further testing of children with allergic symptoms and/or recurrent ACS [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         All episodes of bronchospasm should be recognized early and treated promptly with bronchodilator therapy [
         <a href="#rid7">
          7,9,11,124,125
         </a>
         ]. Appropriate controller therapy with inhaled glucocorticoids is also an important component of care. (See
         <a class="medical medical_review" href="/z/d/html/547.html" rel="external">
          "An overview of asthma management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90904.html" rel="external">
          "Asthma in children younger than 12 years: Overview of initiating therapy and monitoring control"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/562.html" rel="external">
          "Trigger control to enhance asthma management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/566.html" rel="external">
          "Asthma education and self-management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">
          "Acute asthma exacerbations in children younger than 12 years: Emergency department management"
         </a>
         .)
        </p>
        <p>
         Monitoring of pulmonary status is also important, with periodic assessment of resting oxygen concentration by SpO
         <sub>
          2
         </sub>
         and pulmonary function tests to assess for asthma. One approach is to obtain pulmonary function testing starting at age 6 years and repeated at five-year intervals (individuals without asthma or additional ACS episodes) or two to three-year intervals (individuals with a history of asthma or recurrent ACS) [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7121.html" rel="external">
          "Overview of the pulmonary complications of sickle cell disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H955357">
         <span class="h1">
          PREVENTION
         </span>
        </p>
        <p class="headingAnchor" id="H3503838057">
         <span class="h2">
          Risk of ACS recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals who have had an episode of ACS have an increased risk for future episodes.
        </p>
        <p>
         In a study involving 125 children ages 1 to 4 years with Hb SS or Hb S-beta
         <sup>
          0
         </sup>
         -thalassemia who were admitted to the hospital with ACS, 112 (90 percent) had at least one additional episode of vaso-occlusive pain or ACS [
         <a href="#rid126">
          126
         </a>
         ]. Of these, 27 percent had a recurrence within 6 months, 63 percent within 1 year, and 79 percent within 2 years. The proportion taking
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         was not stated.
        </p>
        <p>
         A retrospective study involving 264 children with Hb SS or Hb S-beta
         <sup>
          0
         </sup>
         -thalassemia in the Dallas Newborn Cohort demonstrated that ACS in the first three years of life significantly increased the odds of more frequent episodes of ACS during childhood (odds ratio 2.5; 95% CI 1.7-3.9) [
         <a href="#rid127">
          127
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1450127295">
         <span class="h2">
          Incentive spirometry during hospitalization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Incentive spirometry has been examined as a measure to prevent ACS episodes in children with sickle cell disease (SCD) who were admitted to the hospital for a vaso-occlusive pain episode. Performing incentive spirometry using 10 maximal breaths every two hours while awake was associated with a significantly reduced rate of developing ACS versus no incentive spirometry (5 versus 42 percent) [
         <a href="#rid98">
          98
         </a>
         ]. There have been no studies to determine the efficacy of incentive spirometry to prevent worsening of ACS. However, standard practice includes ongoing use of incentive spirometry when a patient is admitted to the hospital and develops ACS. (See
         <a class="local">
          'Respiratory support'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1103237863">
         <span class="h2">
          Outpatient interventions for prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Interventions to reduce the risk of further ACS episodes are a critical component of management. The key interventions are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prepare for therapy
         </strong>
         – For children at risk for ACS, practice use of a nasal mask when well (during a routine clinic visit) to make use of a nasal mask during treatment of acute ACS more familiar and less frightening.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevent infections
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Provide prophylactic penicillin to children up to at least five years of age. (See
         <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">
          "Overview of the management and prognosis of sickle cell disease", section on 'Prophylactic penicillin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Administer age-appropriate vaccines in all age groups. (See
         <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">
          "Overview of the management and prognosis of sickle cell disease", section on 'Immunizations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Optimize lung health
         </strong>
         – Children and adults with multiple episodes of ACS are typically evaluated for asthma symptoms and atopy, and, if present, environmental preventive strategies and asthma therapies are instituted. (See
         <a class="medical medical_review" href="/z/d/html/547.html" rel="external">
          "An overview of asthma management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Asthma treatment involves establishing care with a pulmonologist. (See
         <a class="local">
          'Discharge planning and outpatient monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For adults with recurrent wheezing and repetitive ACS, there is no evidence-based strategy. Adults with SCD rarely have asthma, and there is not strong evidence that inhaled glucocorticoids affect outcomes.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Although baseline daytime pulse oximetry (SpO
         <sub>
          2
         </sub>
         ) does not predict vaso-occlusive pain or ACS, children with suspected nocturnal hypoxemia (oxygen saturation &lt;93 percent by SpO
         <sub>
          2
         </sub>
         ) and/or prior history of ACS should be considered for polysomnography studies [
         <a href="#rid22">
          22,47,128
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reduce vaso-occlusion
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          Hydroxyurea
         </a>
         is indicated for all individuals with Hb SS or Hb S-beta
         <sup>
          0
         </sup>
         -thalassemia and individuals with other SCD syndromes who have vaso-occlusive complications. (See
         <a class="medical medical_review" href="/z/d/html/7071.html" rel="external">
          "Hydroxyurea use in sickle cell disease", section on 'Indications and evidence for efficacy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Consider chronic transfusions if response to
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         is inadequate. In patients who are recovering from a life-threatening ACS, a six-month transfusion regimen with transition to hydroxyurea therapy is often used. (See
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Acute chest syndrome treatment and prevention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Consider other disease-modifying therapies (
         <a class="drug drug_general" data-topicid="126184" href="/z/d/drug information/126184.html" rel="external">
          crizanlizumab
         </a>
         , L-glutamine) if the response to
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         is inadequate. (See
         <a class="medical medical_review" href="/z/d/html/126298.html" rel="external">
          "Disease-modifying therapies to prevent pain and other complications of sickle cell disease", section on 'Options if hydroxyurea is not tolerated or ineffective in individuals with Hb SS or Hb S-Beta(0)-thalassemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Perioperative period
         </strong>
         – Careful perioperative management, including appropriate presurgical transfusion support and postoperative pulmonary care can minimize risk; details and supporting evidence are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Prophylactic preoperative transfusion'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H330416402">
         <span class="h2">
          Supporting evidence for prevention
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hydroxyurea
         </strong>
         – Multiple randomized trials have demonstrated that
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         markedly decreases the frequency of ACS in children and adults [
         <a href="#rid129">
          129-134
         </a>
         ]. Despite this, hydroxyurea is under-used [
         <a href="#rid135">
          135
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7071.html" rel="external">
          "Hydroxyurea use in sickle cell disease", section on 'Indications and evidence for efficacy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          Hydroxyurea
         </a>
         should be administered by experienced clinicians who can provide informed counseling about the risks and benefits, appropriate dose-titration, and close monitoring for potential toxicities. (See
         <a class="medical medical_review" href="/z/d/html/7071.html" rel="external">
          "Hydroxyurea use in sickle cell disease", section on 'Administration and dosing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7071.html" rel="external">
          "Hydroxyurea use in sickle cell disease", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transfusion
         </strong>
         – Transfusion therapy is an effective intervention for the prevention of recurrent ACS, especially if
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         is insufficiently effective [
         <a href="#rid136">
          136,137
         </a>
         ]. Therapy can be short-term (&lt;6 months) or long-term (&gt;6 months). Short-term transfusion therapy can be used during high risk periods for ACS (winter months with increased frequency of respiratory illnesses) or during the transition to hydroxyurea therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For individuals who have had two or more episodes of moderate to very severe ACS in the past 24 months despite maximal
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         therapy, we may consider chronic exchange transfusions (manual or via erythrocytapheresis). This strategy is rarely used in pediatrics. In one of the contributors' (MDB) center with 300 children and adolescents, there was no case requiring regular blood transfusion to prevent ACS in the last decade, and in 250 adults, only one individual required regular transfusions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For transfusion therapy to attenuate ACS episodes, it should be done every four to six weeks to maintain a hemoglobin S (Hb S) percentage &lt;50 percent and continued for one to two years. The upper limit for Hb S of &lt;50 percent is less stringent than that used to treat acute ACS events or for primary or second stroke prevention. Decision-making, supporting evidence, technical considerations, and risks (infection, iron overload, allosensitization, transfusion reactions) are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/128123.html" rel="external">
          "Transfusion in sickle cell disease: Management of complications including iron overload"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other pharmacologic therapies
         </strong>
         – L-glutamine was approved by the US Food and Drug Administration in 2017. A randomized trial demonstrated that in patients five years of age and older, L-glutamine decreased the incidence of ACS, especially in children [
         <a href="#rid138">
          138
         </a>
         ]. Two-thirds of study participants were also taking
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         . Although L-glutamine and
         <a class="drug drug_general" data-topicid="126184" href="/z/d/drug information/126184.html" rel="external">
          crizanlizumab
         </a>
         do not have sufficient evidence to determine efficacy for preventing ACS, we will consider using them in some cases, as they are effective in reducing pain episodes, and vaso-occlusive pain precedes a significant number of ACS episodes.
         <a class="drug drug_general" data-topicid="126260" href="/z/d/drug information/126260.html" rel="external">
          Voxelotor
         </a>
         also did not have enough evidence to evaluate efficacy in preventing ACS, but voxelotor did not reduce pain in a randomized trial and thus would be less optimal as a preventive therapy for ACS. (See
         <a class="medical medical_review" href="/z/d/html/126298.html" rel="external">
          "Disease-modifying therapies to prevent pain and other complications of sickle cell disease", section on 'Options if hydroxyurea is not tolerated or ineffective in individuals with Hb SS or Hb S-Beta(0)-thalassemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematopoietic stem cell transplantation
         </strong>
         – For patients who have experienced multiple life-threating ACS events and who have an HLA-matched sibling donor, hematopoietic stem cell transplantation is an alternative. While potentially curative, it is not standard practice due to the high toxicity associated with myeloablative regimens. Decision-making, choice of transplant techniques, and supporting evidence is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/5929.html" rel="external">
          "Hematopoietic stem cell transplantation in sickle cell disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H221481">
         <span class="h1">
          LONG-TERM COMPLICATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H1657344192">
         <span class="h2">
          Pulmonary hypertension (PH)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited evidence suggests that repeated ACS episodes are associated with the development of restrictive lung disease (previously referred to as chronic sickle cell lung disease). (See
         <a class="medical medical_review" href="/z/d/html/7121.html" rel="external">
          "Overview of the pulmonary complications of sickle cell disease"
         </a>
         .)
        </p>
        <p>
         The contribution of ACS to the development of PH, if any, is more difficult to discern, especially when different definitions for PH have been used across studies [
         <a href="#rid139">
          139-142
         </a>
         ]. In a study of 195 adults with SCD, elevated tricuspid jet velocity (≥2.5 meters/second), a surrogate for an elevated pulmonary artery pressure, was not associated with repeated ACS episodes [
         <a href="#rid143">
          143
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94999.html" rel="external">
          "Pulmonary hypertension associated with sickle cell disease"
         </a>
         .)
        </p>
        <p>
         All individuals with SCD should have baseline pulmonary function tests (PFTs) and periodic spirometry to monitor for restrictive and obstructive pulmonary disease. In a study of 40 children with SCD in which half had ACS episodes and half did not, those who had an episode of ACS were more likely to have abnormal PFTs (increase in mean airway resistance, total lung capacity, and residual volume) [
         <a href="#rid13">
          13
         </a>
         ]. Additional testing including polysomnography or overnight pulse oximetry may also be useful in selected individuals. (See
         <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">
          "Overview of the management and prognosis of sickle cell disease", section on 'Routine evaluations and treatments'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2641759164">
         <span class="h2">
          Risk of death
         </span>
         <span class="headingEndMark">
          —
         </span>
         In older studies, prior to established clinical guidelines for ACS management and use of
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         , conjugated pneumococcal vaccines, penicillin prophylaxis, and transfusion therapy for acute treatment, ACS was a leading cause of death in SCD, accounting for one-fourth of deaths in some series [
         <a href="#rid144">
          144,145
         </a>
         ]. In the National Acute Chest Syndrome Study Group study, 3 percent of the patients died; all had received mechanical ventilation for respiratory failure [
         <a href="#rid2">
          2
         </a>
         ]. The most common causes of death included pulmonary emboli and infectious bronchopneumonia. In a report from the Cooperative Study of Sickle Cell Disease, the death rate in patients with ACS is 1.1 percent in children and 4.3 percent in adults [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         In the modern era, ACS is a rare cause of death in children and less common cause of death in adults. In a retrospective cohort study of children and adults with SCD from two medical centers, there were no deaths in children; death occurred only in adults with rapidly progressive ACS (in 6.3 percent) [
         <a href="#rid69">
          69
         </a>
         ]. Prospective studies have demonstrated that death in children is very unlikely but the risk has not been eliminated [
         <a href="#rid146">
          146
         </a>
         ]. Rapidly progressive ACS in adults remains a risk factor for death and requires timely clinical intervention with automated exchange transfusion, respiratory support, and monitoring for other organ injury with appropriate interventions. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
         Routine use of
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         may decrease the rates of ACS and ACS mortality. (See
         <a class="medical medical_review" href="/z/d/html/7071.html" rel="external">
          "Hydroxyurea use in sickle cell disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1320614740">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110843.html" rel="external">
          "Society guideline links: Sickle cell disease and thalassemias"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/126613.html" rel="external">
          "Society guideline links: COVID-19 – Index of guideline topics"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1109014199">
         <span class="h1">
          PATIENT PERSPECTIVE TOPIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See
         <a class="medical medical_review" href="/z/d/html/132604.html" rel="external">
          "Patient perspective: Sickle cell disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H955364">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and triggers
         </strong>
         – Acute chest syndrome (ACS) is defined as a new radiodensity on chest imaging with fever and/or respiratory symptoms in an individual with sickle cell disease (SCD). Infection is a common trigger in children; in adults, hospitalization for vaso-occlusive pain is common. The table summarizes these and other differences  (
         <a class="graphic graphic_table graphicRef134346" href="/z/d/graphic/134346.html" rel="external">
          table 1
         </a>
         ). Other triggers include pulmonary infarction, fat embolism, and asthma. (See
         <a class="local">
          'Definitions and pediatric-adult differences'
         </a>
         above and
         <a class="local">
          'Common triggers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Incidence
         </strong>
         – Approximately 50 percent of individuals with SCD will have an ACS episode, children more commonly than adults. The peak incidence in children is two to four years. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical
         </strong>
         – Severity is variable. Common findings include fever, pain (chest, extremities, ribs), dyspnea, and neurologic symptoms. Adults tend to have severe disease and can develop respiratory compromise, respiratory failure, and multiorgan failure. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – Vigilance is required, especially in individuals with SCD hospitalized for any reason. Standardized assessment protocols improve outcomes. Pulse oximetry is important but may underestimate tissue hypoxia. Laboratory testing and chest imaging should be done promptly. Evaluation for pulmonary embolism (PE) and cardiac ischemia may be appropriate. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – A new radiodensity on chest radiography plus fever or respiratory symptoms is confirmatory. The differential diagnosis includes vaso-occlusive pain, severe anemia, multiorgan failure, rib fracture, asthma, PE, pulmonary hypertension, heart failure, and cardiac ischemia. These conditions can accompany or trigger ACS. (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immediate management
         </strong>
         – ACS can be fatal. All patients require urgent attention to:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pain
         </strong>
         <strong>
          control
         </strong>
         – Opioids are typically required, especially for adults. (See
         <a class="local">
          'Pain control'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7144.html" rel="external">
          "Acute vaso-occlusive pain management in sickle cell disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Oxygenation
         </strong>
         – We suggest maintaining a target oxygen saturation ≥95 percent (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Some individuals may require noninvasive or invasive ventilation. (See
         <a class="local">
          'Respiratory support'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antibiotics
         </strong>
         – Antibiotics are used regardless of whether fever is present. We suggest empiric therapy for community-acquired pneumonia (a macrolide plus a third generation cephalosporin) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         may be added for severe disease, and other antibiotics may be reasonable if fever is absent. (See
         <a class="local">
          'Antibiotics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Transfusions
         </strong>
         – Most individuals with ACS, especially adults, should receive transfusions. We recommend urgent exchange transfusion for individuals with clinical deterioration and multiorgan failure (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ). We also suggest transfusion (simple or exchange) for stable patients not requiring significant respiratory support (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The type of transfusion (simple versus exchange) and target hemoglobin and hemoglobin S percentages are discussed above and separately. (See
         <a class="local">
          'Transfusion'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">
          "Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive care
         </strong>
         – As needed supportive care includes fluids and venous thromboembolism (VTE) prophylaxis. Incentive spirometry should be used while awake. (See
         <a class="local">
          'Fluid management'
         </a>
         above and
         <a class="local">
          'Bronchodilators'
         </a>
         above and
         <a class="local">
          'VTE prophylaxis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         – Recurrence risk is high; thoughtful discharge planning helps minimize risk. Preventive interventions include vaccinations, penicillin for young children, asthma medications, and SCD controlling therapies (
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         , perioperative transfusion, chronic transfusion for some individuals). (See
         <a class="local">
          'Discharge planning and outpatient monitoring'
         </a>
         above and
         <a class="local">
          'Prevention'
         </a>
         above and
         <a class="local">
          'Long-term complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H292564704">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic review and was a founding Editor-in-Chief for UpToDate in Hematology.
        </p>
        <p>
         The UpToDate editorial staff also acknowledges extensive contributions of Donald H Mahoney, Jr, MD to earlier versions of the pediatric sections of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Dang NC, Johnson C, Eslami-Farsani M, Haywood LJ. Bone marrow embolism in sickle cell disease: a review. Am J Hematol 2005; 79:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000; 342:1855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994; 84:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glassberg JA, Wang J, Cohen R, et al. Risk factors for increased ED utilization in a multinational cohort of children with sickle cell disease. Acad Emerg Med 2012; 19:664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Field JJ, DeBaun MR. Asthma and sickle cell disease: two distinct diseases or part of the same process? Hematology Am Soc Hematol Educ Program 2009; :45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paul R, Minniti CP, Nouraie M, et al. Clinical correlates of acute pulmonary events in children and adolescents with sickle cell disease. Eur J Haematol 2013; 91:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyd JH, Moinuddin A, Strunk RC, DeBaun MR. Asthma and acute chest in sickle-cell disease. Pediatr Pulmonol 2004; 38:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood 2006; 108:2923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knight-Madden JM, Forrester TS, Lewis NA, Greenough A. Asthma in children with sickle cell disease and its association with acute chest syndrome. Thorax 2005; 60:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willen SM, Rodeghier M, Strunk RC, et al. Aeroallergen sensitization predicts acute chest syndrome in children with sickle cell anaemia. Br J Haematol 2018; 180:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bryant R. Asthma in the pediatric sickle cell patient with acute chest syndrome. J Pediatr Health Care 2005; 19:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sylvester KP, Patey RA, Broughton S, et al. Temporal relationship of asthma to acute chest syndrome in sickle cell disease. Pediatr Pulmonol 2007; 42:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sylvester KP, Patey RA, Milligan P, et al. Impact of acute chest syndrome on lung function of children with sickle cell disease. J Pediatr 2006; 149:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sylvester KP, Patey RA, Rafferty GF, et al. Airway hyperresponsiveness and acute chest syndrome in children with sickle cell anemia. Pediatr Pulmonol 2007; 42:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Setty BN, Stuart MJ, Dampier C, et al. Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. Lancet 2003; 362:1450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen RT, Madadi A, Blinder MA, et al. Recurrent, severe wheezing is associated with morbidity and mortality in adults with sickle cell disease. Am J Hematol 2011; 86:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glassberg JA, Chow A, Wisnivesky J, et al. Wheezing and asthma are independent risk factors for increased sickle cell disease morbidity. Br J Haematol 2012; 159:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melton CW, Haynes J Jr. Sickle acute lung injury: role of prevention and early aggressive intervention strategies on outcome. Clin Chest Med 2006; 27:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wales PW, Carver E, Crawford MW, Kim PC. Acute chest syndrome after abdominal surgery in children with sickle cell disease: Is a laparoscopic approach better? J Pediatr Surg 2001; 36:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kokoska ER, West KW, Carney DE, et al. Risk factors for acute chest syndrome in children with sickle cell disease undergoing abdominal surgery. J Pediatr Surg 2004; 39:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyder O, Yaster M, Bateman BT, Firth PG. Surgical procedures and outcomes among children with sickle cell disease. Anesth Analg 2013; 117:1192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham LM Jr. The effect of sickle cell disease on the lung. Clin Pulm Med 2004; 11:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hargrave DR, Wade A, Evans JP, et al. Nocturnal oxygen saturation and painful sickle cell crises in children. Blood 2003; 101:846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen RT, DeBaun MR, Blinder MA, et al. Smoking is associated with an increased risk of acute chest syndrome and pain among adults with sickle cell disease. Blood 2010; 115:3852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadreameli SC, Kopp BT, Creary SE, et al. Secondhand Smoke Is an Important Modifiable Risk Factor in Sickle Cell Disease: A Review of the Current Literature and Areas for Future Research. Int J Environ Res Public Health 2016; 13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dean D, Neumayr L, Kelly DM, et al. Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease. J Pediatr Hematol Oncol 2003; 25:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vichinsky EP, Styles LA, Colangelo LH, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood 1997; 89:1787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neumayr L, Lennette E, Kelly D, et al. Mycoplasma disease and acute chest syndrome in sickle cell disease. Pediatrics 2003; 112:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkpatrick MB, Haynes J. Sickle cell disease and pulmonary circulation. Semin Resp Crit Care Med 1994; 15:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mekontso Dessap A, Deux JF, Abidi N, et al. Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 2011; 184:1022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowenthal EA, Wells A, Emanuel PD, et al. Sickle cell acute chest syndrome associated with parvovirus B19 infection: case series and review. Am J Hematol 1996; 51:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norris CF, Smith-Whitley K, McGowan KL. Positive blood cultures in sickle cell disease: time to positivity and clinical outcome. J Pediatr Hematol Oncol 2003; 25:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willen SM, Rodeghier M, DeBaun MR. Asthma in children with sickle cell disease. Curr Opin Pediatr 2019; 31:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madhi F, Kamdem A, Jung C, et al. Identification of Clinical and Laboratory Parameters Associated with the Development of Acute Chest Syndrome during Vaso-Occlusive Episodes in Children with Sickle Cell Disease: A Preliminary Step before Assessing Specific and Early Treatment Strategies. J Clin Med 2019; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maitre B, Habibi A, Roudot-Thoraval F, et al. Acute chest syndrome in adults with sickle cell disease. Chest 2000; 117:1386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godeau B, Schaeffer A, Bachir D, et al. Bronchoalveolar lavage in adult sickle cell patients with acute chest syndrome: value for diagnostic assessment of fat embolism. Am J Respir Crit Care Med 1996; 153:1691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaidi Y, Sivakumaran M, Graham C, Hutchinson RM. Fatal bone marrow embolism in a patient with sickle cell beta + thalassaemia. J Clin Pathol 1996; 49:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scully RE, Mark EJ, McNeely WF, et al. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 20-1997. A 74-year-old man with progressive cough, dyspnea, and pleural thickening. N Engl J Med 1997; 336:1895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutchinson RM, Merrick MV, White JM. Fat embolism in sickle cell disease. J Clin Pathol 1973; 26:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lechapt E, Habibi A, Bachir D, et al. Induced sputum versus bronchoalveolar lavage during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 2003; 168:1373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rayburg M, Kalinyak KA, Towbin AJ, et al. Fatal bone marrow embolism in a child with hemoglobin SE disease. Am J Hematol 2010; 85:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ataga KI, Orringer EP. Bone marrow necrosis in sickle cell disease: a description of three cases and a review of the literature. Am J Med Sci 2000; 320:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vichinsky E, Williams R, Das M, et al. Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia. Blood 1994; 83:3107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro MP, Hayes JA. Fat embolism in sickle cell disease. Report of a case with brief review of the literature. Arch Intern Med 1984; 144:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garza JA. Massive fat and necrotic bone marrow embolization in a previously undiagnosed patient with sickle cell disease. Am J Forensic Med Pathol 1990; 11:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008; 359:2254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham LM. Sickle cell disease: pulmonary management options. Pediatr Pulmonol Suppl 2004; 26:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyd JH, DeBaun MR, Morgan WJ, et al. Lower airway obstruction is associated with increased morbidity in children with sickle cell disease. Pediatr Pulmonol 2009; 44:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           PELTIER LF. Fat embolism. III. The toxic properties of neutral fat and free fatty acids. Surgery 1956; 40:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Telen MJ. Role of adhesion molecules and vascular endothelium in the pathogenesis of sickle cell disease. Hematology Am Soc Hematol Educ Program 2007; :84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program 2007; :91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballas SK, Files B, Luchtman-Jones L, et al. Secretory phospholipase A2 levels in patients with sickle cell disease and acute chest syndrome. Hemoglobin 2006; 30:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris CR, Kuypers FA, Larkin S, et al. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol 2000; 22:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris CR, Kuypers FA, Lavrisha L, et al. Elevated arginase activity and limited arginine bioavailability: a common feature of asthma and sickle cell disease [Abstract]. Blood 2003; 102:764a.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaar V, Tarer V, Etienne-Julan M, et al. ET-1 and ecNOS gene polymorphisms andsusceptibility to acute chest syndrome and painful vaso-occlusive crises in children with sickle cell anemia. Haematologica 2006; 91:1277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duckworth L, Hsu L, Feng H, et al. Physician-diagnosed asthma and acute chest syndrome: associations with NOS polymorphisms. Pediatr Pulmonol 2007; 42:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham JK, Mosunjac M, Hanzlick RL, Mosunjac M. Sickle cell lung disease and sudden death: a retrospective/prospective study of 21 autopsy cases and literature review. Am J Forensic Med Pathol 2007; 28:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darbari DS, Kple-Faget P, Kwagyan J, et al. Circumstances of death in adult sickle cell disease patients. Am J Hematol 2006; 81:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manci EA, Culberson DE, Yang YM, et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol 2003; 123:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haque AK, Gokhale S, Rampy BA, et al. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol 2002; 33:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collins FS, Orringer EP. Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies. Am J Med 1982; 73:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adedeji MO, Cespedes J, Allen K, et al. Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med 2001; 125:1436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutton LL, Castro O, Cross DJ, et al. Pulmonary hypertension in sickle cell disease. Am J Cardiol 1994; 74:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gendreau S, Scholer M, Cecchini J, et al. Cerebral fat embolism in sickle cell disease. Am J Hematol 2020; 95:E41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsitsikas DA, Vize J, Abukar J. Fat Embolism Syndrome in Sickle Cell Disease. J Clin Med 2020; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsitsikas DA, May JE, Gangaraju R, et al. Revisiting fat embolism in sickle syndromes: diagnostic and emergency therapeutic measures. Br J Haematol 2019; 186:e112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassell KL, Eckman JR, Lane PA. Acute multiorgan failure syndrome: a potentially catastrophic complication of severe sickle cell pain episodes. Am J Med 1994; 96:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballas SK, Lieff S, Benjamin LJ, et al. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol 2010; 85:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaturvedi S, Ghafuri DL, Glassberg J, et al. Rapidly progressive acute chest syndrome in individuals with sickle cell anemia: a distinct acute chest syndrome phenotype. Am J Hematol 2016; 91:1185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henderson JN, Noetzel MJ, McKinstry RC, et al. Reversible posterior leukoencephalopathy syndrome and silent cerebral infarcts are associated with severe acute chest syndrome in children with sickle cell disease. Blood 2003; 101:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee KH, McKie VC, Sekul EA, et al. Unusual encephalopathy after acute chest syndrome in sickle cell disease: acute necrotizing encephalitis. J Pediatr Hematol Oncol 2002; 24:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeBaun MR, Schatz J, Siegel MJ, et al. Cognitive screening examinations for silent cerebral infarcts in sickle cell disease. Neurology 1998; 50:1678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clift AK, Saatci D, Coupland CAC, et al. Sickle Cell Disorders and Severe COVID-19 Outcomes: A Cohort Study. Ann Intern Med 2021; 174:1483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nur E, Gaartman AE, van Tuijn CFJ, et al. Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19). Am J Hematol 2020; 95:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hussain FA, Njoku FU, Saraf SL, et al. COVID-19 infection in patients with sickle cell disease. Br J Haematol 2020; 189:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crabtree EA, Mariscalco MM, Hesselgrave J, et al. Improving care for children with sickle cell disease/acute chest syndrome. Pediatrics 2011; 127:e480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reagan MM, DeBaun MR, Frei-Jones MJ. Multi-modal intervention for the inpatient management of sickle cell pain significantly decreases the rate of acute chest syndrome. Pediatr Blood Cancer 2011; 56:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blaisdell CJ, Goodman S, Clark K, et al. Pulse oximetry is a poor predictor of hypoxemia in stable children with sickle cell disease. Arch Pediatr Adolesc Med 2000; 154:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed S, Siddiqui AK, Sison CP, et al. Hemoglobin oxygen saturation discrepancy using various methods in patients with sickle cell vaso-occlusive painful crisis. Eur J Haematol 2005; 74:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan RP, Grant JN, Kaufman AJ. Dermatologic features of the fat embolism syndrome. Cutis 1986; 38:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Styles LA, Aarsman AJ, Vichinsky EP, Kuypers FA. Secretory phospholipase A(2) predicts impending acute chest syndrome in sickle cell disease. Blood 2000; 96:3276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bargoma EM, Mitsuyoshi JK, Larkin SK, et al. Serum C-reactive protein parallels secretory phospholipase A2 in sickle cell disease patients with vasoocclusive crisis or acute chest syndrome. Blood 2005; 105:3384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Styles LA, Abboud M, Larkin S, et al. Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2. Br J Haematol 2007; 136:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris C, Vichinsky E, Styles L. Clinician assessment for acute chest syndrome in febrile patients with sickle cell disease: is it accurate enough? Ann Emerg Med 1999; 34:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colla JS, Kotini-Shah P, Soppet S, et al. Bedside ultrasound as a predictive tool for acute chest syndrome in sickle cell patients. Am J Emerg Med 2018; 36:1855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Preto-Zamperlini M, Giorno EPC, Bou Ghosn DSN, et al. Point-of-care lung ultrasound is more reliable than chest X-ray for ruling out acute chest syndrome in sickle cell pediatric patients: A prospective study. Pediatr Blood Cancer 2022; 69:e29283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charache S, Scott JC, Charache P. "Acute chest syndrome" in adults with sickle cell anemia. Microbiology, treatment, and prevention. Arch Intern Med 1979; 139:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stuart MJ, Setty BN. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood 1999; 94:1555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies SC, Luce PJ, Win AA, et al. Acute chest syndrome in sickle-cell disease. Lancet 1984; 1:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lakkireddy DR, Patel R, Basarakodu K, Vacek J. Fatal pulmonary artery embolism in a sickle cell patient: case report and literature review. J Thromb Thrombolysis 2002; 14:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mekontso-Dessap A, Deux JF, Abidi N, et al. Pulmonary thromboembolism during acute chest syndrome in sickle cell disease. Eur Resp J 2011; 38:2342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogunbayo GO, Misumida N, Olorunfemi O, et al. Comparison of Outcomes in Patients Having Acute Myocardial Infarction With Versus Without Sickle-Cell Anemia. Am J Cardiol 2017; 120:1768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kress JP, Pohlman AS, Hall JB. Determination of hemoglobin saturation in patients with acute sickle chest syndrome: a comparison of arterial blood gases and pulse oximetry. Chest 1999; 115:1316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rackoff WR, Kunkel N, Silber JH, et al. Pulse oximetry and factors associated with hemoglobin oxygen desaturation in children with sickle cell disease. Blood 1993; 81:3422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitzgerald RK, Johnson A. Pulse oximetry in sickle cell anemia. Crit Care Med 2001; 29:1803.
          </a>
         </li>
         <li class="breakAll">
          Lane PA, Buchanan GR, Hutter JJ, et al. Sickle cell disease in children and adolescents: diagnosis, guidelines for comprehensive care, and care paths and protocols for management of acute and chronic complications. Sickle Cell Disease Consortium, by permission, 2003.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellet PS, Kalinyak KA, Shukla R, et al. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med 1995; 333:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang CJ, Kavanagh PL, Little AA, et al. Quality-of-care indicators for children with sickle cell disease. Pediatrics 2011; 128:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu LL, Batts BK, Rau JL. Positive expiratory pressure device acceptance by hospitalized children with sickle cell disease is comparable to incentive spirometry. Respir Care 2005; 50:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padman R, Henry M. The use of bilevel positive airway pressure for the treatment of acute chest syndrome of sickle cell disease. Del Med J 2004; 76:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghuram N, Pettignano R, Gal AA, et al. Plastic bronchitis: an unusual complication associated with sickle cell disease and the acute chest syndrome. Pediatrics 1997; 100:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moser C, Nussbaum E, Cooper DM. Plastic bronchitis and the role of bronchoscopy in the acute chest syndrome of sickle cell disease. Chest 2001; 120:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trant CA Jr, Casey JR, Hansell D, et al. Successful use of extracorporeal membrane oxygenation in the treatment of acute chest syndrome in a child with severe sickle cell anemia. ASAIO J 1996; 42:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pelidis MA, Kato GJ, Resar LM, et al. Successful treatment of life-threatening acute chest syndrome of sickle cell disease with venovenous extracorporeal membrane oxygenation. J Pediatr Hematol Oncol 1997; 19:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knight-Madden JA, Hambleton IR. Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease. Cochrane Database Syst Rev 2003; :CD003733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopel LS, Klings ES, Monuteaux MC, et al. Bronchodilator Use for Acute Chest Syndrome Among Large Pediatric Hospitals in North America. Clin Pediatr (Phila) 2018; 57:1630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dolatkhah R, Dastgiri S. Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database Syst Rev 2020; 1:CD007843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emre U, Miller ST, Gutierez M, et al. Effect of transfusion in acute chest syndrome of sickle cell disease. J Pediatr 1995; 127:901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohene-Frempong K. Indications for red cell transfusion in sickle cell disease. Semin Hematol 2001; 38:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Claster S, Vichinsky EP. Managing sickle cell disease. BMJ 2003; 327:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Telen MJ. Principles and problems of transfusion in sickle cell disease. Semin Hematol 2001; 38:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lombardo T, Rosso R, La Ferla A, et al. Acute Chest Syndrome: the role of erythro-exchange in patients with sickle cell disease in Sicily. Transfus Apher Sci 2003; 29:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velasquez MP, Mariscalco MM, Goldstein SL, Airewele GE. Erythrocytapheresis in children with sickle cell disease and acute chest syndrome. Pediatr Blood Cancer 2009; 53:1060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaartman AE, Sayedi AK, Gerritsma JJ, et al. Fluid overload due to intravenous fluid therapy for vaso-occlusive crisis in sickle cell disease: incidence and risk factors. Br J Haematol 2021; 194:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernini JC, Rogers ZR, Sandler ES, et al. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 1998; 92:3082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobota A, Graham DA, Heeney MM, Neufeld EJ. Corticosteroids for acute chest syndrome in children with sickle cell disease: variation in use and association with length of stay and readmission. Am J Hematol 2010; 85:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strouse JJ, Takemoto CM, Keefer JR, et al. Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. Pediatr Blood Cancer 2008; 50:1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med 1994; 330:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan KJ, Goodwin SR, Evangelist J, et al. Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent. Crit Care Med 1999; 27:2563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atz AM, Wessel DL. Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology 1997; 87:988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Head CA, Brugnara C, Martinez-Ruiz R, et al. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo. J Clin Invest 1997; 100:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maitre B, Djibre M, Katsahian S, et al. Inhaled nitric oxide for acute chest syndrome in adult sickle cell patients: a randomized controlled study. Intensive Care Med 2015; 41:2121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leong MA, Dampier C, Varlotta L, Allen JL. Airway hyperreactivity in children with sickle cell disease. J Pediatr 1997; 131:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koumbourlis AC, Zar HJ, Hurlet-Jensen A, Goldberg MR. Prevalence and reversibility of lower airway obstruction in children with sickle cell disease. J Pediatr 2001; 138:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vance LD, Rodeghier M, Cohen RT, et al. Increased risk of severe vaso-occlusive episodes after initial acute chest syndrome in children with sickle cell anemia less than 4 years old: Sleep and asthma cohort. Am J Hematol 2015; 90:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quinn CT, Shull EP, Ahmad N, et al. Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia. Blood 2007; 109:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uong EC, Boyd JH, DeBaun MR. Daytime pulse oximeter measurements do not predict incidence of pain and acute chest syndrome episodes in sickle cell anemia. J Pediatr 2006; 149:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvarez O, Yovetich NA, Scott JP, et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol 2013; 88:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010; 85:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2010; 115:2354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003; 289:1645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 2005; 106:2269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program 2009; :62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hankins J, Jeng M, Harris S, et al. Chronic transfusion therapy for children with sickle cell disease and recurrent acute chest syndrome. J Pediatr Hematol Oncol 2005; 27:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr 2001; 139:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niihara Y, Miller ST, Kanter J, et al. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med 2018; 379:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suell MN, Bezold LI, Okcu MF, et al. Increased pulmonary artery pressures among adolescents with sickle cell disease. J Pediatr Hematol Oncol 2005; 27:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qureshi N, Joyce JJ, Qi N, Chang RK. Right ventricular abnormalities in sickle cell anemia: evidence of a progressive increase in pulmonary vascular resistance. J Pediatr 2006; 149:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee MT, Small T, Khan MA, et al. Doppler-defined pulmonary hypertension and the risk of death in children with sickle cell disease followed for a mean of three years. Br J Haematol 2009; 146:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagar RW, Michlitsch JG, Gardner J, et al. Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. Br J Haematol 2008; 140:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas AN, Pattison C, Serjeant GR. Causes of death in sickle-cell disease in Jamaica. Br Med J (Clin Res Ed) 1982; 285:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nouraie M, Darbari DS, Rana S, et al. Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The PUSH study. Am J Hematol 2020; 95:766.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16353 Version 44.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15849760" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Bone marrow embolism in sickle cell disease: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10861320" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7517723" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22687181" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Risk factors for increased ED utilization in a multinational cohort of children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20008181" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Asthma and sickle cell disease: two distinct diseases or part of the same process?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23560516" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical correlates of acute pulmonary events in children and adolescents with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15274102" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Asthma and acute chest in sickle-cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16690969" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15741436" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Asthma in children with sickle cell disease and its association with acute chest syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29363738" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Aeroallergen sensitization predicts acute chest syndrome in children with sickle cell anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15867831" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Asthma in the pediatric sickle cell patient with acute chest syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17186507" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Temporal relationship of asthma to acute chest syndrome in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16860119" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Impact of acute chest syndrome on lung function of children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17262858" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Airway hyperresponsiveness and acute chest syndrome in children with sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14602439" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21809369" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Recurrent, severe wheezing is associated with morbidity and mortality in adults with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22966893" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Wheezing and asthma are independent risk factors for increased sickle cell disease morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16880058" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Sickle acute lung injury: role of prevention and early aggressive intervention strategies on outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11329573" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Acute chest syndrome after abdominal surgery in children with sickle cell disease: Is a laparoscopic approach better?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15185210" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Risk factors for acute chest syndrome in children with sickle cell disease undergoing abdominal surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24108258" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Surgical procedures and outcomes among children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The effect of sickle cell disease on the lung
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393400" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Nocturnal oxygen saturation and painful sickle cell crises in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20448118" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Smoking is associated with an increased risk of acute chest syndrome and pain among adults with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27845754" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Secondhand Smoke Is an Important Modifiable Risk Factor in Sickle Cell Disease: A Review of the Current Literature and Areas for Future Research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12544773" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9057664" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12837872" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Mycoplasma disease and acute chest syndrome in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Sickle cell disease and pulmonary circulation
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21836136" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8619401" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Sickle cell acute chest syndrome associated with parvovirus B19 infection: case series and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12759626" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Positive blood cultures in sickle cell disease: time to positivity and clinical outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31090576" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Asthma in children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31683997" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Identification of Clinical and Laboratory Parameters Associated with the Development of Acute Chest Syndrome during Vaso-Occlusive Episodes in Children with Sickle Cell Disease: A Preliminary Step before Assessing Specific and Early Treatment Strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10807826" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Acute chest syndrome in adults with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8630622" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Bronchoalveolar lavage in adult sickle cell patients with acute chest syndrome: value for diagnostic assessment of fat embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9038769" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Fatal bone marrow embolism in a patient with sickle cell beta + thalassaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9197219" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 20-1997. A 74-year-old man with progressive cough, dyspnea, and pleural thickening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4733865" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Fat embolism in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12969866" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Induced sputum versus bronchoalveolar lavage during acute chest syndrome in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20131308" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Fatal bone marrow embolism in a child with hemoglobin SE disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11093689" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Bone marrow necrosis in sickle cell disease: a description of three cases and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8193347" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6691757" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Fat embolism in sickle cell disease. Report of a case with brief review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2305755" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Massive fat and necrotic bone marrow embolization in a previously undiagnosed patient with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19020327" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Pulmonary complications of sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15029648" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Sickle cell disease: pulmonary management options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19205057" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Lower airway obstruction is associated with increased morbidity in children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13371426" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Fat embolism. III. The toxic properties of neutral fat and free fatty acids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18024614" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Role of adhesion molecules and vascular endothelium in the pathogenesis of sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18024615" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Hypercoagulability in sickle cell disease: new approaches to an old problem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16798640" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Secretory phospholipase A2 levels in patients with sickle cell disease and acute chest syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11132219" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Elevated arginase activity and limited arginine bioavailability: a common feature of asthma and sickle cell disease [Abstract]
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16956834" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : ET-1 and ecNOS gene polymorphisms andsusceptibility to acute chest syndrome and painful vaso-occlusive crises in children with sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17351927" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Physician-diagnosed asthma and acute chest syndrome: associations with NOS polymorphisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17525572" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Sickle cell lung disease and sudden death: a retrospective/prospective study of 21 autopsy cases and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16924640" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Circumstances of death in adult sickle cell disease patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14531921" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Causes of death in sickle cell disease: an autopsy study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12395378" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7148875" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11697998" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Pulmonary thrombotic arteriopathy in patients with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8074054" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Pulmonary hypertension in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31736103" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Cerebral fat embolism in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33171683" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Fat Embolism Syndrome in Sickle Cell Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31044433" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Revisiting fat embolism in sickle syndromes: diagnostic and emergency therapeutic measures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8109600" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Acute multiorgan failure syndrome: a potentially catastrophic complication of severe sickle cell pain episodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19902523" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Definitions of the phenotypic manifestations of sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27543812" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Rapidly progressive acute chest syndrome in individuals with sickle cell anemia: a distinct acute chest syndrome phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393443" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Reversible posterior leukoencephalopathy syndrome and silent cerebral infarcts are associated with severe acute chest syndrome in children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12368703" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Unusual encephalopathy after acute chest syndrome in sickle cell disease: acute necrotizing encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9633710" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cognitive screening examinations for silent cerebral infarcts in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34338553" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Sickle Cell Disorders and Severe COVID-19 Outcomes: A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32267016" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32314798" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : COVID-19 infection in patients with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21242225" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Improving care for children with sickle cell disease/acute chest syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21157894" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Multi-modal intervention for the inpatient management of sickle cell pain significantly decreases the rate of acute chest syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10980793" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Pulse oximetry is a poor predictor of hypoxemia in stable children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15777343" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Hemoglobin oxygen saturation discrepancy using various methods in patients with sickle cell vaso-occlusive painful crisis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3731870" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Dermatologic features of the fat embolism syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11050014" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Secretory phospholipase A(2) predicts impending acute chest syndrome in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15802550" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Serum C-reactive protein parallels secretory phospholipase A2 in sickle cell disease patients with vasoocclusive crisis or acute chest syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17156397" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10381996" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Clinician assessment for acute chest syndrome in febrile patients with sickle cell disease: is it accurate enough?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30017686" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Bedside ultrasound as a predictive tool for acute chest syndrome in sickle cell patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34931750" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Point-of-care lung ultrasound is more reliable than chest X-ray for ruling out acute chest syndrome in sickle cell pediatric patients: A prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32855" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : "Acute chest syndrome" in adults with sickle cell anemia. Microbiology, treatment, and prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10477680" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Sickle cell acute chest syndrome: pathogenesis and rationale for treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6140352" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Acute chest syndrome in sickle-cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12652154" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Fatal pulmonary artery embolism in a sickle cell patient: case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Pulmonary thromboembolism during acute chest syndrome in sickle cell disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28867123" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Comparison of Outcomes in Patients Having Acute Myocardial Infarction With Versus Without Sickle-Cell Anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10334146" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Determination of hemoglobin saturation in patients with acute sickle chest syndrome: a comparison of arterial blood gases and pulse oximetry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25203083" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7685205" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Pulse oximetry and factors associated with hemoglobin oxygen desaturation in children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11546990" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Pulse oximetry in sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11546990" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Pulse oximetry in sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7637747" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21844055" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Quality-of-care indicators for children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15871756" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Positive expiratory pressure device acceptance by hospitalized children with sickle cell disease is comparable to incentive spirometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15212227" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : The use of bilevel positive airway pressure for the treatment of acute chest syndrome of sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9200374" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Plastic bronchitis: an unusual complication associated with sickle cell disease and the acute chest syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11502666" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Plastic bronchitis and the role of bronchoscopy in the acute chest syndrome of sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8725698" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Successful use of extracorporeal membrane oxygenation in the treatment of acute chest syndrome in a child with severe sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9329470" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Successful treatment of life-threatening acute chest syndrome of sickle cell disease with venovenous extracorporeal membrane oxygenation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12917983" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30173539" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Bronchodilator Use for Acute Chest Syndrome Among Large Pediatric Hospitals in North America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31942751" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Blood transfusions for treating acute chest syndrome in people with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8523186" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Effect of transfusion in acute chest syndrome of sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11206961" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Indications for red cell transfusion in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14615343" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Managing sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11605166" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Principles and problems of transfusion in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12877891" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Acute Chest Syndrome: the role of erythro-exchange in patients with sickle cell disease in Sicily.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19637317" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Erythrocytapheresis in children with sickle cell disease and acute chest syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34263922" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Fluid overload due to intravenous fluid therapy for vaso-occlusive crisis in sickle cell disease: incidence and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9787142" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19957348" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Corticosteroids for acute chest syndrome in children with sickle cell disease: variation in use and association with length of stay and readmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17849474" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8107739" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10579281" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9357905" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Inhaled nitric oxide in sickle cell disease with acute chest syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9276736" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26431718" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Inhaled nitric oxide for acute chest syndrome in adult sickle cell patients: a randomized controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9290616" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Airway hyperreactivity in children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11174615" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Prevalence and reversibility of lower airway obstruction in children with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25619382" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Increased risk of severe vaso-occlusive episodes after initial acute chest syndrome in children with sickle cell anemia less than 4 years old: Sleep and asthma cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16940426" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17095349" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Daytime pulse oximeter measurements do not predict incidence of pain and acute chest syndrome episodes in sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23861242" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7715639" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20513116" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19903897" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12672732" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16172253" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20008183" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Advances in the use of hydroxyurea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15750449" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Chronic transfusion therapy for children with sickle cell disease and recurrent acute chest syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11743502" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30021096" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16344670" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Increased pulmonary artery pressures among adolescents with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16860121" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Right ventricular abnormalities in sickle cell anemia: evidence of a progressive increase in pulmonary vascular resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19563512" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Doppler-defined pulmonary hypertension and the risk of death in children with sickle cell disease followed for a mean of three years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17916102" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Clinical differences between children and adults with pulmonary hypertension and sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14985486" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7993409" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Mortality in sickle cell disease. Life expectancy and risk factors for early death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6819042" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Causes of death in sickle-cell disease in Jamaica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32243618" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The PUSH study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
